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 Bacteria are ubiquitous and vital constituents of our environment, our foods, and our 
bodies.   A small percentage of this vast, microbial population is pathogenic to humans, but 
represents a significant burden on public health.  There is a current public health focus on two 
subgroups: foodborne pathogenic bacteria and antibiotic resistance bacteria.  A key challenge 
for public health is the rapid identification of these bacteria to prevent their consumption and to 
ensure proper treatment for infections.  This challenge calls for the development of novel, low-
cost diagnostics that combine sensitivity and accuracy with speed and ease-of-use.  
Bacteriophages represent rapid, readily targeted, and easily produced probes for the 
detection of bacterial pathogens.  Furthermore, modern molecular tools have allowed 
researchers to make significant advances in the bioengineering of bacteriophage to further 
improve speed and sensitivity of detection.  Our work here demonstrates the successful 
bioengineering of bacteriophage to create platforms that: (i) enable multiplex detection of 
bacterial pathogens; (ii) allow for the rapid detection of antibiotic resistant bacteria; (iii) and can 




In particular we demonstrate: (i) the modification of T7 bacteriophage to carry TEV 
protease enabling proof-of-principle detection of E. coli in 3 hours after a primary enrichment 
via TEV protease activity using a fluorescent peptide and using a designed target peptide for 
MALDI-TOF MS analysis; (ii) the development and use of a phage amplification-based lateral 
flow assay for the detection of low levels of E. coli in less than 7 hours in both broth and water; 
and (iii) the modification of T7 phage to carry phoA;  enabling the rapid detect of low levels of 
bacteria and their antibiotic susceptibility in under 6 hours.  These phage-based platforms could 
be readily adopted in many labs without significant capital investments and can be translated to 
other phage-bacteria pairs for further detection.  Further research into the bioengineering of 
phage-based reporters and demonstrating their incorporation into common and novel 
diagnostics platforms, will highlight their potential and ideally result in the creation of 
diagnostics that impact public health. 
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CHAPTER 1 BACTERIOPHAGE: POTENTIAL APPLCATIONS FOR RESOURCE-LIMITED DIAGNOSTICS 
1.1 Introduction 
Bacteria are an integral part of our world.  They are present in the environment that surrounds 
us, the food and water we consume, and are vital inhabitants of our bodies.  Of this vast bacterial 
population, a small percentage is pathogenic to humans, but this group represents a significant burden 
on public health.  At both the national and global level, there has been increasing focus by public health 
agencies on the prevalence of foodborne pathogenic bacteria1-3, as well as the rise and dissemination of 
antibiotic resistance bacteria4-7.  A key challenge in both these areas is the rapid identification of these 
bacteria to: (i) prevent the distribution and consumption of contaminated foods and water8-10; or (ii) to 
ensure rapid and proper treatment post-infection11.   This challenge is further acerbated by global and 
within-country disparities in economic, technological, and regulatory capabilities12-14.  For example, 
implementation of a mandatory PCR-based bacterial screening of foods by producers could be feasible 
in resource-rich, politically stable countries, but impractical for small producers or within countries that 
lack the basic resources required like electricity, access to supplies, financials, and as educated 
workforce.  These added challenges in resource-limited settings, have driven research into the 
development of  “lab-on-chip” technologies15 aimed at addressing issues with manufacturing, detection, 
automation, and power source to create diagnostics that are simple, cheap, and reliable and thus 
amenable to adoption in such settings. 
Paper-fluidic 16, 17 and microfluidic 18, 19 based devices have proven themselves to be effective 
platforms for the detection of chemicals and pathogenic organisms of interest in resource-limited 
settings 14, and there is a large body of research applying them for detection of various bacterial, 
chemical, viral agents20-23.  The home pregnancy is perhaps the best recognized embodiment of a paper-
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fluidic device, and highlights the simplicity, cost-effectiveness, and reliability of the lateral flow assay 
(LFA).   The recent introduction of the home use HIV test kits24, further demonstrates the successful 
adoption of the lateral flow platform in real world diagnostics addressing public health.    These 
technologies have begun to replace more traditional culture based methods, in both primary and third 
party testing laboratories, to enable rapid screening of samples.  Commercially available examples of 
these LFA based products are the Lateral Flow System by DuPont (Wilmington, DE) and  Neogen’s Reveal 
2.0 product line, both of which have dipstick assays for the detection E. coli O157:H7, Salmonella spp., 
and Listeria (Neogen, Ann Harbor, MI).   
1.2 The Lateral Flow Assay 
The schematic of a lateral flow assay is fairly simple. In its most common form, the LFA consists 
of a nitrocellulose membrane, containing a test line, control line, with a sample and conjugate pad at 
one end, and an adsorbent pad at the other.  The test line is composed of a capture agent against the 
target molecule being measured.  Typically, the capture agent is either: (i) an antibody against the 
specific target, like a protein, bacterial surface antigen, or chemical 20, 21, 25-27 ; or (ii) the capture agent 
can be a DNA aptamer against a specific target DNA sequence17, 28-30; though any capture system, like 
biotin-streptavidin, can be leveraged if appropriate.  The sample pad, as its name implies, is where an 
aliquot of the test sample is placed.  From the sample pad, the solution flows through the conjugate 
pad.  If the LFA is a sandwich assay, the conjugate pad contains a secondary detector antibody or DNA 
aptamer against the test’s target molecule.  If it is a competitive assay, the conjugate pad contains the 
target molecule.  In either of these assay formats, the conjugate pad contained detector or target 
molecule is linked to a reporter molecule.  There are a various reporters molecules utilized, like colloidal 
gold or fluorescent particles17, 21, 28, as well as enzymatic reporters, like alkaline phosphatase, that enable 
colorimetric, fluorescent, chemiluminescent, or electrochemical detection21, 31-34.   In the sandwich assay, 
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the reporter-tagged detector binds the target molecule, which flows up the strip and is captured at the 
test line, producing a signal there.  In the competitive assay, the untagged target molecule in the sample 
and the tagged target in the conjugate pad both run up the strip and compete for space at the test line.  
If the sample contains the target, there is an elimination or reduction in signal at the test line vs the 
control.  The absorbent pad wicks up the solution, drawing the entire sample up past the test line.   
1.3 Challenges for Lateral Flow Assays 
While immuno-based LFAs have been successful applied for the detection many pathogenic 
organisms, there are potential drawbacks with the use of antibodies.  The first is the expense and time 
to produce the antibody for a given target21, 35.  Second is the limited specificity of antibodies there by 
limiting detection of a broad range of closely related molecules. It would be  difficulty to develop a 
mixture of antibodies with a broad enough range to capture an entire species of bacteria, such as the 
generic E. coli which is commonly used as indicator of water quality36 or Salmonella spp. which has over 
2000 serotypes37.  Thirdly, there are potential false positives that may result with antibody cross-
reactivity, or in the case of bacterial antibodies attaching to components of non-viable cells, resulting in 
a false-positive test result38, 39.  DNA-based LFAs also have the potential for false positives due to the 
presence of extraneous DNA from non-viable cells40. 
Another challenge for LFAs is the limited sample size and sample composition.  Test sample sizes 
typically range from 50 µL – 100 µL, meaning that the target molecule may need to be at concentration 
levels not typically found in real world samples to be detected.  LFA’s by their design require a sample 
matrix that can flow up the test strip, which limits testing to sample matrices with low viscosity.  
Furthermore, sample color, clarity, ionic strength, and the presence of particulates, may also adversely 
affect flow and the ability to detect visual, fluorescent, or electrochemical signals at the test line.  The 
sample may also contain compounds that inhibit PCR or other enzymatic reporters, leading to false 
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negatives.  Conversely, the sample may contain endemic enzymes, fluorescent compounds, or genetic 
material that result in the production of false positives for a given method.  LFA’s are thus often with a 
separation methods to reduce the impact of this potential sample interference.  Some of these methods 
have the added benefit of concentrating the target molecule 41.  LFAs have been combined with 
membrane filter, phase separation42, and immuno-magnetic separation43 steps to concentrate the target 
of interest. In some cases, an amplification step is also used to increase the target concentration or 
signal.  Examples of amplification for LFA would be the use of a traditional bacterial enrichment step 
prior to testing, like in Neogen’s Reveal 2.0 tests, or the use of a preliminary PCR step to amplify a target 
DNA sequence within a sample21, 29.   
1.4 Bacteriophage - Potential Applications 
Bacteriophages (phages) are a class of virus that infects prokaryotic bacteria.  They were first 
discovered in 1915, and initially used as antimicrobial agents but were quickly supplanted by 
antibiotics44.  Phages play an important role in various industries like: dairy fermentation where they 
represent a significant product quality threat45; for bacterial strain typing based on phage susceptibility 
patterns46-49, and as biocontrols for foodborne pathogens50-53.  Our increased understanding of phage 
diversity, and the creative applications of modern bioengineering tools, has lead to renewed interest in 
bacteria phage.  There are clearly opportunities to leverage these advances and apply phage to enhance 
diagnostics, like paper-fluidic LFAs, geared to resource-limited settings. 
1.4.1 Bacteriophage as Detection Agents 
Phages are becoming increasingly popular as probes in bacterial detection schemes50, 54-56.   
Phages have several potential advantages over other detection probes, like antibodies and DNA.  First, 
phages are relatively easy to produce as they are readily propagated in the presence of their host54 and 
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can be subsequently purified for use57, 58.  A second advantage is that phage are host specific, and a 
single or multiple phage types can be used to target a specific bacterial strain, species, or group of 
closely related bacterial species54, 56.  The successful use of reporter-tagged phage for bacterial detection 
has been demonstrated using both fluorescently59-61 and enzymatically62 tags.    The VIDAS® UP by 
Biomérieux (St. Louis, MO) is a commercially available detection platform that utilizes reporter-tagged 
phage components as detector probes in an ELISA format for the detection of Salmonella, E. coli 
O157:H7, and Listeria with reported superior performance to PCR-based methods63.  Phage-display 
schemes have also allowed for the development of novel phage-based probes by enabling the 
bioengineering of phage capsids to incorporate proteins with affinities to chemicals and molecule 
unrelated to bacterial detection64. 
1.4.2 Bacteriophage as Agents for Signal Amplification 
The use of phages as a detection probes also allows for signal amplification, commonly referred 
to as phage amplification. In concept, a single phage adsorbs to and infects a single bacterial cell.  The 
phage DNA is injected into the host, and through a series of mechanisms, it commandeers the metabolic 
machinery of the cell into the production of new phage.  At the  end of the infection cycle holin and 
lysozyme are produced, rupturing the cell wall, and releasing tens to hundreds of new phage into the 
environment. The E. coli phage T7, for example, has an infection-to-lysis time of  25 minutes under ideal 
conditions65, and over 100 new phage released at the end of a cycle66.  For comparison, E. coli cells take 
approximately the same amount of time to replicate under optimal growth conditions67, so a traditional 
bacterial enrichment for amplification results in only 2-fold increase using versus the potential 100-fold 
increase in T7 phage in the same amount of time.  There other phages with burst sizes greater than a 
1000-fold68, making their incorporation into bacterial detection schemes quite attractive.  Furthermore, 
since phage replication requires healthy, growing bacterial cells, detection of phage amplification can be 
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used to specifically identify the presence of only viable cells in a sample. This is another advantage 
phage-based detection schemes have over immunological and PCR-based schemes40, 69, which may 
detect extraneous antigens or DNA from non-viable cells resulting in higher false positive rates9, 39, 40, 69. 
Advances in molecular techniques, have enabled the combination of both phage and enzyme 
based amplification for bacterial detection.  Phages have been genetically modified to express reporter 
enzymes with high turnover rates, enabling more rapid and sensitive detection. Luciferase has been 
successfully incorporated into several phage strains targeting bacterial pathogens like E. coli O157:H770, 
Yersinia pestis71, and Bacillus anthracis72. Commercially, Sample6 (Boston, MA) has developed a phage-
based bioluminescent enzymatic reporter platform for the detection of Listeria in environmental 
samples.  In the literature luciferase appears to be a popular choice as an enzymatic reporter, but recent 
research has also shown the successful incorporation of enzymes like peroxidases73, proteases74, and 
alkaline phosphatase75 as phage-mediated reporters. 
1.4.3 Bacteriophage as Agents for Bacterial Separation and Concentration 
Phage-host cell binding dynamics make phage an attractive alternative capture agent in place of 
antibodies in IMS based schemes41. Once a phage attaches to a cell, the bond is very strong and 
irreversible76 in comparison to antibody-antigen bonds which are reversible77.  Recent research has 
demonstrated the successful application of both phage78 and phage components79 as antibody 
replacements in these IMS based scheme.  If the phage virions conjugated to magnetic beads are 
infectious, and the target cells captured viable, there exists the potential to create novel detection 
schemes that combine bacterial separation, concentration, and phage based amplification. 
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1.4.4 Bacteriophage as Agents for the Detection of Antibiotic Resistance 
In the area of antibiotic susceptibility testing, the application of phage for the rapid detection of 
antimicrobial resistance is still in its infancy11, 80, 81.  The  FDA had approved a phage amplification-based 
lateral flow device for the rapid detection of methicillin resistant (MRSA) S. aureus 82,  called KeyPathTM  
by MicroPhage Inc. (Longmont, CO) but the assay is no longer available83.  DNA-based methods are 
quickly replacing traditional culture-based methods, and many of these new methods are automated, 
which is an adoption hurdle for the LFA format, like that used by MicroPhage, in high-throughput clinical 
testing labs that focus on antibiotic susceptibility testing.   DNA-based antibiotic resistance systems have 
achieved expansive screening capabilities84, but there remains a large reservoir of unknown antibiotic 
resistance genes85 and resistance mechanisms86, 87, making exhaustive DNA-based screening 
unattainable.  There is also the issue of gene expression in resistance, as there is the potential for a gene 
conferring resistance to a given antibiotic to be present, but not properly expressed.  DNA-based 
methods that screen for gene presence but not regulation could result in unnecessarily intensive 
treatments, with potentially more undesirable side effects, being employed to fight an infection.  Phage 
amplification-based screening, because it relies on the phenotypic rather than genotypic state of the 
cells, sidesteps some of these DNA-based issues.  Phage amplification requires viable bacterial cells, and 
thus amplification is contingent upon bacterial growth in the presence of the antibiotic.  Nothing must 
be known about potential resistance mechanisms a priori to this phage-based testing.  Phage 
amplification-based testing also allows for the implementation of several internal quality controls.  The 
first is the elimination of false positives due to the cross-contamination of a test by an internal 
laboratory strain with resistance.  If the contaminating strain is of a different species to that of the test 
strain, phage amplification will not occur whereas a traditional test looking for sample turbidity or a 
DNA–based test screening only for genes would result in a false positive signal in this scenario.  There is 
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the issue of bacterial strains acquiring phage resistance, potential resulting in the very undesirable false 
negative for resistance.  An assay control that includes growing the isolate in the presence of the phage 
but not the antibiotic would allow phage resistance to be flagged, and prompt for confirmation via 
alternative method.   These advantages suggest there are still untapped applications for phage-based 
antibiotic susceptibility testing. 
1.5 Conclusion 
Phages represent multifaceted building blocks that can be incorporated as substitutes for, or in 
unison with other detection methods, to create powerful new diagnostics for the detection of bacteria.  
The ease of phage manipulation, production, and detection speed clearly highlights that there yet 
remains unrealized opportunities to leverage these phage-based components in diagnostics amenable 
to resource-limited settings.  The passage of regulations like the Food Safety Modernization act, and the 
ever increasing extent of global trade and travel, will create further demand for these types of 
diagnostics.  While phage-based diagnostics have begun to entering the market place, further research 
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CHAPTER 2 RESULTS OF A PILOT ANTIBIOTIC RESISTANCE SURVEY OF ALBANIAN POULTRY FARMS 
2.1 Abstract 
Goal: The global dissemination of antibiotic-resistant bacteria in food animals is a major public 
health concern. While many countries have implemented prudent antibiotic use policies and 
surveillance systems in both clinical and veterinary settings, there are no such systems in place in 
Albania and little is known about the levels of antibiotic resistance bacteria in food animals within the 
country.  
Methods: A total 172 poultry samples were taken from six Albanian farms over a 3 month period 
and tested for the presence of Enterobacteriacae.  A total of 91 bacterial isolates were obtained and 
were characterized by species (Escherichia coli, Salmonella, or other Enterobacteriacae) and by 
susceptibility to 11 antibiotics. 
Results:  E. coli and Salmonella isolates exhibited resistance to amoxicillin (86%, 64%), 
chloramphenicol (77%, 82%), ciprofloxacin (93%, 73%), cefotaxime (14%, 0%), gentamicin (12%, 0%), 
kanamycin (30%, 18%), nalidixic acid (91%, 73%), streptomycin (70%, 55%), sulphonamides (91%, 73%), 
tetracycline (95%, 73%), and trimethoprim (79%, 64%) respectively.  Multidrug resistance to at least 4 
antibiotics was observed in 95% of E. coli isolates and 82% of Salmonella.  
Conclusions: Our data indicate that: (i) Salmonella and E. coli isolates from Albanian poultry 
farms exhibit high to extremely high levels of antibiotic resistance; (ii) Salmonella and E. coli isolates 
exhibit resistance to multiple antibiotics; and (iii) multidrug resistant profiles among Enterobacteriacae 
are geographically widespread. Implementation of prudent antibiotic use policies in food animals and 
related surveillance will be necessary to reduce the emergence, spread, and establishment of highly 
resistant strains across poultry farms in Albania.   
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2.2 Introduction 
In response to rising rates of antibiotic resistance among clinical bacterial isolates and data 
linking antibiotic use to resistance development 12, 88, 89, leading public health organizations such as the 
World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC) in the United 
States of America, and the Royal Society of Medicine have published recommendations calling for: (i) 
prudent use of antimicrobials, (ii) improved surveillance of antimicrobial use and resistance, and (iii) 
awareness campaigns for both health professionals and the public on the control and risks of 
antimicrobial resistance 90.  Research has also highlighted the public health impact of veterinary 
antibiotic use and the movement of antibiotic resistant bacteria between animal and human 
populations 91, 92.  While antibiotics are commonly used to treat, prevent, and control diseases in food 
animals, as well promote growth, sufficient data detailing the amount and frequency of antibiotic use in 
animal husbandry is lacking 93.  Institutions such as the European Food Safety Agency (EFSA), European 
Centre for Disease Prevention and Control (ECDC), the European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC), and the National Antimicrobial Resistance Monitoring System for Enteric Bacteria 
(NARMS) in the United States, have been vital in illuminating the interplay between human and animal 
populations, antimicrobial use, and antimicrobial resistance.  The monitoring systems supported by 
these institutions, however, are primarily focused on Western Europe and North America, obscuring the 
global picture of antibiotic resistance.  Research suggests that the prevalence of antibiotic resistant 
bacteria is much higher in other regions 13. The globalization of the food supply chain and increased 
global travel means that antibiotic practices and prevalence of antibiotic resistant bacteria within these 
countries will have public health implications well beyond their borders.  It is therefore critical to 
develop a more precise picture of global antibiotic resistance, identify public health risks, and 
implement appropriate strategies for control where appropriate. 
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Albania is located in southeastern Europe, and in 2014 it became an official candidate for 
accession to the European Union.  Albania currently lacks surveillance programs for antibiotic 
consumption and resistance, and so it is difficult to gauge the potential health impacts of increasing 
travel and trade.   Recent surveys have found poor control and misuse of clinically important antibiotics 
94, 95.  Agricultural exports are an important economic focus for Albania, but local food safety standards 
represent a hurdle for export growth 96. There is little peer-reviewed published material on antibiotic 
use or antibiotic resistant bacterial levels in food animals in this country.   
In this paper we report the results of a short-term pilot surveillance study initiated as part of a  
joint WHO-World Organization for Animal Health (OIE) project on “National Human and Animal Health 
Systems Assessment Tools and Bridges” to gain a preliminary understanding of bacterial  resistance 
levels in food animals in Albania.  This pilot survey looked at antibiotic resistance levels in 
Enterobacteriacae, with a focus on Salmonella and E. coli, isolated from across six poultry farms over a 
three month period.  To put these results in context, we compared them to the antimicrobial resistance 
levels in poultry reported by EFSA for the EU.  We hope the results of this pilot will call attention to the 
antibiotic related policies in Albania, and support the long-term implementation of robust surveillance 
and prudent use programs.  
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2.3 Materials and Methods 
2.3.1 Bacterial Isolates 
All isolates included in this study were obtained as part of a field survey examining the levels of 
antibiotic resistance on Albanian poultry farms. Isolates included in this study were cultured from 172 
poultry samples of the neck skin, stomach, intestines & stomach, or cloacal swabs from slaughtered 
poultry.  Samples were collected from six Albanian farms, during three visits to each farm from 
December 2013 to early February 2014 (Figure 2.1).  Samples were processed using ISO 6579: 2002 
“Microbiology of food and animal feeding stuffs – horizontal method for the detection of Salmonella 
spp.” Subsequently, all colonies, including those that were not Salmonella-like on selective media, were 
characterized biochemically using API 20E (bioMérieux, Durham, NC, United States).  For the purposes of 
this study, isolates were classified as E. coli, Salmonella spp., or “other Enterobacteriaceae” (e.g. 
Klebsiella spp., Citrobacter spp., etc).  All Salmonella spp. were serotyped. A total of 91 bacterial isolates 
were cultured from the 172 samples, including 3 samples which yielded two isolates each.  There were 
84 negative samples. 
2.3.2 Antibiotic Resistance Profiles.  
 All isolates were characterized for susceptibility to 11 antibiotics: amoxicillin (amo), 
chloramphenicol (chl), ciprofloxacin (cip), cefotaxime (ctx), gentamicin (gen), kanamycin (kan), nalidixic 
acid (nal), streptomycin (str), sulphonamides (sul), tetracycline (tet), and trimethoprim (tmp), using MIC 
Test strips (Liofilchem Diagnostics, Roseto degli Abruzzi, Italy).   Interpretation was based on the 
epidemiological cut-off values (ECOFFs) from the European Committee on Antimicrobial Susceptibility 
Testing website 97.  Salmonella ECOFF’s for kan and sul were listed as not determined, so the published 
E. coli ECOFF’s values were used for analysis.  The antibiotic resistance of isolates identified as other 
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Enterobacteriacae, were also interpreted using the reported E. coli ECOFFs.  Once resistance to the 11 
antibiotics was interpreted for all isolates, each unique resistance pattern was assigned a resistance 
profile number. This isolate data was used to determine the percentage of resistance to a given 
antibiotic, the frequency distribution of multidrug resistance, and the geographic distribution of species 
specific resistance profiles.  
 
Figure 0.1 Distribution of antibiotic resistance profiles across Albanian poultry farms. Farm location followed by (number of bacterial isolates / total number of samples taken).  For each farm a box contains the profile number, and the letters in parenthesis indicate isolate type: e - E. coli, s - Salmonella, b – Enterobacteriacae with the profile. 
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2.4 Results and Discussion 
This pilot antibiotic resistance surveillance survey encompassed six of the twelve large 
commercial Albanian poultry farms, over a three month period from December 2013 to early February 
2014. These farms process an estimated 800,000 to 1,200,000 chickens a year. A total 172 poultry 
samples were taken, yielding 91 bacterial isolates.  Isolates were characterized by species (Salmonella, E. 
coli, or other Enterobacteriacae) and by susceptibility to 11 antibiotics. All Salmonella isolates obtained 
were identified as enteritidis by serotyping.  There were 92 neck skin samples taken, which yielded 1 
Salmonella, 9 E. coli, and 22 Enterobacteriaceae isolates. Of the 20 stomach samples taken, 4 
Salmonella, 7 E. coli, and 4 Enterobacteriaceae isolates were obtained. Of the 6 intestine samples taken, 
no Salmonella, 1 E. coli, and 3 Enterobacteriaceae isolates were obtained. Of the 12 stomach & intestine 
samples taken, 2 Salmonella, 2 E. coli, and 1 Enterobacteriaceae isolates were obtained. Of the 42 
cloacal swabs taken, 4 Salmonella, 24 E. coli, and 7 Enterobacteriaceae isolates were obtained.  
2.4.1 Bacterial Isolates from Albanian Poultry Show High to Extremely High Levels of Antibiotic Resistance 
 In 2012, the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance 
(AGISAR) released the 3rd revision of critically important and highly important antibiotics for human 
medicine 98.  High levels of resistance to these antibiotics in food animal bacterial isolates have serious 
implications for general public health, safety of farm workers and their families, and the efficacy of 
veterinary treatments to control animal disease on-farm.  Our data (Table 1) show there are reasons for 
concern about the antibiotic resistance situation in Albania.   
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Our pilot study found extremely high levels of resistance, > 70% as defined by the joint EFSA and 
ECDC EU summary report on antimicrobial resistance 7, to seven of the eleven antibiotics included (Table 
2.1) in E.coli isolated from poultry.  In contrast, the results of the 2012 EU summary report, no country 
reported E. coli from poultry exhibiting extremely high levels of resistance to any of the antibiotics 
tested 7.  Our study also found moderate levels of resistance to gentamicin and very high levels of 
resistance to streptomycin (Table 2.1), in contrast to low levels of resistance to gentamicin and high 
levels of resistance to streptomycin in the EU report7.  Our study found moderate levels of resistance to 
cefotaxime, which was similar to the level of resistance in E. coli isolates from poultry reported in the EU 
report.  Salmonella isolates from Albania poultry showed extremely high levels of resistance to 5 of the 
antibiotics included (Table 2.1).  In contrast, no EU country reported Salmonella spp. isolates from 
poultry exhibiting extremely high levels of resistance to any of the antibiotics tested 7.  The EU summary 
did report low levels of resistance to cefotaxime and gentamicin 7, in contrast our study found no 
Salmonella isolates exhibiting resistance to either of these antibiotics.   
 
Currently, Albania has no systems in place for the surveillance of veterinary antibiotic 
consumption, so it is not possible to confidently correlate usage patterns with the patterns of resistance 
found on in our study.  There are, however, some insights worth noting that were gained through 
Species (Total #) AMOa CHLb CIPa CTXa GENa KANa NALa STRa SULb TETb TMPb
E. coli (43) 86% 77% 93% 14% 12% 30% 91% 70% 91% 95% 79%
Enterobacteriacae (37) 84% 62% 78% 8% 8% 16% 73% 54% 84% 78% 54%
Salmonella (11) 64% 82% 73% 0% 0% 18% 73% 45% 73% 73% 64%
All Isolates (91) 82% 71% 85% 10% 9% 23% 81% 60% 86% 86% 67%
Antibiotics Included for Susceptibility Testing
aCritically Important Antibiotic as defined by WHO; bHighly Important Antibiotic as defined by WHO; Terms 
used to describe the antimicrobial resistance levels are: rare, <0.1 %; very low, 0.1 % to 1 %; low,  >1 % to 10 %; 
moderate, >10 % to 20 %; high, >20 % to 50 %; very high, >50 % to 70 %; and extremely high, >70 %. 
Table 0.1 Bacterial isolates showing antibiotic resistance 
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private discussions with Albanian veterinary public health officials with practical knowledge and 
exposure to antibiotic usage on-farm.  The first was regarding fluoroquinolone usage, which was said to 
be widespread and for prolonged periods on poultry farms, for therapeutic and preventive purposes, 
which correlates with the extremely high levels of resistance to naldixic acid (81%) and ciprofloxacin 
(85%) in this study’s isolates.  Conversely, gentamicin, kanamycin, and cefotaxime, are not known to be 
used in Albanian poultry, which may explain in part the low levels of resistance to the agents observed 
in this study.  Lastly, it was indicated, while official numbers were lacking, that there was significant 
qualitative use, both individually and mixed, of antibiotics on Albanian farms.  Further studies and data 
are clearly needed in the area of antibiotic consumption in Albania. Nevertheless, our observations 
suggest that antibiotic resistance levels reflect usage practices on poultry farms in Albania.  
2.4.2 Salmonella and E. coli Isolates Exhibit Resistance to Multiple Antibiotics 
Over 80% of the Salmonella isolates, 9 out of 11, showed resistance to at least 4 antibiotics 
included, and 7 isolates, over 60%, showed resistance to at least 7 of the antibiotics included, none were 
susceptible to all (Figure 2.2).  In contrast, countries in the EU summary report did not report more than 
50% of the Salmonella poultry isolates displaying resistance to 4 or more antibiotics, and not more than 
10% displaying resistance to 7 or more 7.  Our study also found that 95% of the E. coli isolates, 41 of 43, 
showed resistance to at least 4 antibiotics, and 35 isolates, over 80%, with resistance to at least 7 
antibiotics (Figure 2.2).  Again in contrast, no country in the EU summary reported more than 40% of 
poultry E. coli isolates displaying resistance to 4 or more antibiotics, and none reported more than 5% 
with resistance to 7 or more antibiotics 7.  It is also interesting to note that high levels of multidrug 
resistance in other Enterobacteriacae suggesting there is antibiotic resistance selection and 
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maintenance across many bacterial species on Albanian poultry farms.
 
Figure 0.2 Frequency distribution of bacterial isolates resistant to one to ten antibiotics from Albanian poultry. Numbers in parenthesis indicate number of isolates. 
2.4.3 Multidrug Resistant Profiles are Geographically Widespread in Albania Poultry Production 
A total of 42 unique resistance patterns were identified among the isolates included.  Of these, 
11 patterns were either found in multiple species or across multiple farms (Figure 2.1).  Profiles with 
multidrug resistance to the majority of antibiotics tested, like profile 5 and 17 which show resistance to 
9 and 8 of the antibiotics respectively, were found on at least half of the farms sampled.   The 
distribution of these profiles across several species in a single location, for example profile 17 in Lushnje 
or profile 20 in Elbasan (Figure 2.1), could be indicative of on-farm horizontal transfer of antibiotic 
resistance genes between species.  The presence of the same resistance profile in the same species 
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across multiple locations, for example for profile 5 and 17 in E. coli (Figure 2.1), may also be indicative of 
clonal spread of antibiotic resistance across the country. Further genetic characterization of these 
isolates would provide valuable information to determine the extent of horizontal gene transfer 
between species and whether these resistant isolates represent geographically disperse yet clonally 
related populations.  These molecular capabilities were not available in the lab where the pilot 
program’s isolate characterization was performed.  Further work is needed to understand the spread of 
these multidrug resistant strains among livestock farms, and to prevent further spread and potential 
transmission to the public.  
2.5 Conclusion 
In summary, our pilot study indicates that antibiotic resistance among bacterial isolates from 
poultry is much higher in Albania when compared to EU countries.  Furthermore, many isolates also 
exhibited resistance to multiple antibiotics and are widely distributed across the poultry farms surveyed 
in Albania.  These high levels of antibiotic resistance are significant and constitute a public health 
concern.  Further research is needed to understand the levels of and linkages between on-farm 
antibiotic consumption and antibiotic resistance in Albanian, as are policies that establish systems for 
the monitoring of these trends and that encourage prudent antibiotic use. 
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CHAPTER 3 PHAGE & PHOSPHATASE: A NOVEL PHAGE-BASED PROBE FOR RAPID, MULTI-PLATFORM DETECTION 
OF BACTERIA 
3.1 Abstract 
Genetic engineering of bacteriophages allows for the development of rapid, highly specific, and 
easily manufactured probes for the detection of bacterial pathogens.  A challenge for novel probes is the 
ease of their adoption in real world laboratories.  We have engineered the bacteriophage T7, which 
targets Escherichia coli, to carry the alkaline phosphatase gene, phoA. This inclusion results in phoA 
overexpression following phage infection of E. coli.  Alkaline phosphatase is commonly used in a wide 
range of diagnostics, and thus a signal produced by our phage-based probe could be detected using 
common laboratory equipment. Our work demonstrates the successful:  i) modification of T7 phage to 
carry phoA; ii) overexpression of alkaline phosphatase in E. coli; and iii) detection of this T7-induced 
alkaline phosphatase activity using commercially available colorimetric and chemilumiscent methods.  
Furthermore, we demonstrate the application of our phage-based probe to rapidly detect low levels of 
bacteria and discern the antibiotic resistance of E.coli isolates. Using our bioengineered phage-based 
probe we were able to detect 103 CFU/mL of E. coli in 6 hours using a chemiluminescent substrate and 
104 CFU/mL within 7.5 hours using a colorimetric substrate.  We also show the application of this phage-
based probe for antibiotic resistance testing.  We were able to determine whether an E. coli isolate was 
resistant to ampicillin within 4.5 hours using chemiluminescent substrate and within 6 hours using a 
colorimetric substrate.  This phage-based scheme could be readily adopted in labs without significant 
capital investments and can be translated to other phage-bacteria pairs for further detection. 
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3.2 Introduction 
Pathogenic bacteria represent a significant burden on public and economic health 99-101.  The 
need for rapid and accurate detection of these pathogens, in both clinical and industrial settings, has 
spawned a large biosensor industry with a market potential over 500 million USD102.  The search for 
new, innovative approaches to detection has driven research into novel probes that exploit molecular 
interactions, such as bacteriophage, for diagnostic use.  A bacteriophage (phage), is a virus which 
specifically targets bacteria.  Phages were first discovered in 1915 and used as antimicrobials, but were 
quickly supplanted in many areas of the world by the discovery and use of antibiotics44.  The increasing 
prevalence of antibiotic resistant bacteria and modern development of molecular tools enabling the 
specific bioengineering of phages with novel functions has renewed interest in bacteriophages55, 103.  
Phage can be highly specific, they can replicate quickly, and they can be readily propagated.  These 
traits, along with their ability to deliver genetic material to bacterial cells, make them ideal candidates 
for use as molecular probes for pathogen detection 54.  
Phage-based diagnostics have a wide range of applications.  In response to foodborne illness, 
and more recently the passage of the Food Safety Modernization Act, much research has focused on 
developing phage-based methods for the detection of low concentrations of pathogenic bacteria50, 54. 
The fruits of this research are represented commercially by phage-based diagnostics like VIDAS® UP 
(Biomérieux, St. Louis, MO) which uses phage components for the detection of Salmonella, E. coli 
O157:H7, and Listeria, and Sample6 which uses a phage-based bioluminescent reporter for the 
detection of Listeria in environmental samples.   
In the area of antibiotic susceptibility testing, rapid DNA-based methods are increasingly 
supplanting traditional testing methods, but there has been little research into the actual application 
phage-based detection systems to this area11, 80, 81.  While the detection range of DNA-based multiplex 
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systems has become quite expansive84, there is a vast reservoir of unknown genes conferring 
resistance85 and novel mechanisms of resistance being discovered regularly,86, 87, making exhaustive 
testing difficult and possibly resulting in false negatives during testing of clinical isolates.  There is also 
the possibility that genes encoding resistance are present, but not expressed, resulting in a false positive 
and unnecessary antibiotic treatment.  Phage-based antibiotic susceptible testing avoids these issues by 
focusing on the phenotypic status of the cell, bacterial isolate growth in the presence of the antibiotic, 
rather than its genotypic status.  Phage-based detection also provides several quality controls for 
testing.  Despite the use of proficiency testing, many antibiotic susceptibility labs around the world do 
not have the appropriate quality control systems in place104.  Phage host specificity means that potential 
cross-contamination of an antibiotic susceptible isolate’s test by another laboratory isolates of a 
different species with resistance will not result in a positive signal as it might with a traditional or DNA–
based susceptibility test.  There is the possibility that a bacterial strain is resistant to the reporter phage 
used and not the antibiotic, resulting in a false positive.  A simple test control that includes growing the 
isolate in the presence of the phage but without the antibiotic would catch this lack of signal due to 
phage resistance.  These benefits make a strong case the application of phage in novel diagnostics for 
susceptibility testing. 
Challenges for the successful adoption of new diagnostics, particularly in resource limited 
settings, are their cost, required maintenance, and technician training needed for their operation105.  We 
propose a phage-based alkaline phosphatase probe that can be leveraged in a range of detection 
platforms commonly found in microbiology testing labs (Figure 3.1). This scheme would potentially 
reduce the need for new equipment while allowing for the rapid and sensitive detection of bacteria.  
Alkaline phosphatase is frequently used as an enzymatic reporter in many diagnostics, its activity can be 
measured using colorimetric, fluorescent, chemiluminescent, bioluminescent, and electrochemical 
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methods34, 35, 106.  This allows for the potential application of our phage-based platform in widely 
available commercial diagnostics already optimized for alkaline phosphatase detection. 
 
As a proof-of-principle, we bioengineered the E. coli specific T7 phage 65 to carry the E. coli gene 
encoding alkaline phosphatase (phoA)107.  We linked phoA to the T7 promoter for overexpression of 
alkaline phosphatase upon T7 infection of and replication within viable E. coli, and demonstrate the 
detection this T7-mediated alkaline phosphatase activity using commercially available colorimetric and 
chemilumiscent methods.  E. coli is commonly used as an indicator of water quality 36, and pathogenic 
strains of E. coli are responsible for urinary tract infections108, as well as foodborne illnessess1.  Antibioitc 
resistant E. coli also represent a challenge when treating infections in clincal settings109, thus novel 
methods that improve time-to-detection of E. coli are of interest. While others have used E. coli specific 
phage for either colorimetric73 or bioluminescent 70 detection, to our knowledge we are the first to have 
successfully  inserted a gene for alkaline phosphatase54, 56, 103.   We demonstrate potential applications of 
our phage-based probe to: i) enable the detection of low concentrations of E. coli cells, (103-104 CFU/mL) 
in 6-8 hours in broth; and ii) improve time to result for antibiotic susceptibility testing of bacterial 
isolates.  Future work will be necessary to demonstrate the robustness of this concept in more complex 
sample matrices, but we believe this scheme can be readily reproduced using other phage-bacteria 
Figure 0.3 Phage-based probe.  T7phoA is added to a sample. If viable E. coli are present within the sample, phage infection, replication, and alkaline phosphatase overexpression occurs. The alkaline phosphatase reporter can then be detected being using a variety of substrates. 
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combinations, and could be easily adopt in many laboratories without the need for added equipment or 
media. 
3.3 Materials and Methods 
3.3.1 Bacterial Strains, Bacteriophage Strains, Media Culture, and Enumeration. 
The following bacterial and bacteriophage strains were purchased from EMD Millipore (Billerica, 
Massachusetts):  E .coli BL21, E. coli BLT5403, and bacteriophage T7Select® 415-1.  Overnight cultures of 
both E. coli strains used in this study were grown at 37 °C with 200 rpm shaking in 35 mL of Luria Broth 
(LB), pH 7.5, contained in a 150 mL Erlenmeyer flask. Before use overnight cultures were serially diluted 
and plated on LB agar to confirm bacterial concentration for subsequent experiments.    A double agar 
overlay plaque assay on LB110 was used to enumerate phage samples.  The only modification to above 
procures was the inclusion of 100 µg/mL of ampicillin to broth and agar for the growth of E. coli BLT5403 
to maintain its plasmid for resistance 111. 
3.3.2 Construction and Isolation of Engineered Bacteriophage 
In order to modify a T7 phage that carries the E. coli gene for alkaline phosphatase (phoA) we 
designed a specific construct, 1743 base pairs in size, to enable T7-induced overexpression of phoA in E. 
coli within a pUC57 plasmid by GenScript USA Inc. (Piscataway, NJ). Our phoA construct was amplified 
with standard M13 forward and reverse primers using the iProof high-fidelity PCR kit (Bio-Rad 
Laboratories, Hercules, CA).  All PCR products were purified with the QIAquick PCR Purification Kit 
(Qiagen, Valencia, CA), and digested by EcoRI and HindIII.  These restriction enzymes were purchased 
from New England Biolabs (Ipswich, MA).  Our digested construct was then ligated into the T7 Select® 
415-1 genome vector arms using T4 DNA ligase (Promega, Madison, WI) and packaged using the T7 
Select® packing kits (EMD Millipore) to create T7phoA (Figure 3.2). We used the T7 Select® kit’s packaging 
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control DNA, which contains the S•TagTM, as a control phage, T7control (Figure 3.2), which could not 
induce alkaline phosphatase overexpression.  Following packing, T7phoA and T7control were propagated and 
plated as outlined by the T7 Select® kit’s protocol.  Individual plaques were selected, dipped into 100 µL 
of LB, and stored at 4 °C.  All isolated plaques were PCR screened for the appropriate size insert with the 
T7Select® Up and Down primers using the iProof PCR kit.   Plaques containing the appropriate sized 
insert were propagated on E. coli BL21, and the resulting lysates re-screened to confirm the presence of 
our phoA insert.  These lysates were passed through a 0.22 µm SCFA filter (Corning Life Science, Corning, 
NY), tittered, and stored at 4 °C and used as our T7phoA and T7control phage stock for the further 
experiments. 
 
3.3.3 Colorimetric Detection of Alkaline Phosphatase Activity 
Colorimetric detection of alkaline phosphatase activity was performed using the SensoLyte® 
pNPP Alkaline Phosphatase Assay Kit (AnaSpec, Inc., San Jose, CA).  The sample (50 µL) was mixed with 
50 µL of the kit’s  p-Nitrophenyl Phosphate (pNPP) colorimetric alkaline phosphatase substrate in a clear 
96-well plate, incubated at 37 °C, and absorbance at 405nm read every 10 minutes, over 90 minutes, 
Figure 0.4 Diagram of DNA Constructs. (A) Our construct containing phoA. (B) Genome of T7 Select® 415-1 indicating 10B capsid protein and insertion site. (C) Genome of T7phoA. (D) Genome of T7control with S•TagTM. 
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using the Synergy 2 plate reader (BioTek Instruments, Inc., Winooski, VT). Blanks consisted of LB and 
pNPP substrate. 
3.3.4 Chemiluminescent Detection of Alkaline Phosphatase Activity 
Chemiluminescent detection was performed with two substrates.  The first was alkaline 
phosphatase substrate Lumigen APS-5 (Lumigen, Inc., Southfield, MI). 50 µL of sample was mixed with 
50 µL of APS-5 in a black 96-well plate at room temperature.  Blanks consisted of LB and substrate. The 
plates were immediately read using a Synergy2 plate reader (BioTek Instruments, Inc., Winooski, VT) 
with Ex/Em filters Plug/460 nm.   
The second method of chemiluminescent detection was performed using components of the 
Phospha-Light™ SEAP Reporter Gene Assay Kit (Thermo Fisher Scientific Inc., Waltham, MA).  A 50 µL 
aliquot of a 1:20 dilution of the kit’s CSPD® chemiluminescent substrate in the kit’s reaction buffer, 
which contains the EmeraldTM chemiluminescence enhancer, was mixed with 50 µL of sample in a black 
96-well plate at room temperature.  Blanks consisted of LB and substrate.  Plates were place in the 
Synergy2 plate reader (BioTek Instruments, Inc., Winooski, VT) for 10 minutes and read with Ex/Em 
filters set to Plug/Hole, respectively.   
3.3.5 Confirming Alkaline Phosphatase Overexpression 
Six 150 mL Erlenmeyer flasks containing 35 mL of LB were each inoculated with a 150 µL aliquot 
of an overnight culture of BL21.  These flasks were then incubated at 37 °C for 3 hours with 200 rpm 
shaking, and the cultures confirmed to have reached and O.D.600 > 0.6.  Three cultures were then 
inoculated with 15 µL of T7phoA phage stock, and the remaining three inoculated with 15 µL of T7control 
phage stock.  The cultures were incubated for 2 hours under the same conditions.  The resulting lysates 
were then transferred to a 50 mL conical tube tubes and spun at 7598 × g on a Fiberlite F21-8x50y fixed 
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angle rotor (Thermo Fisher Scientific Inc., Waltham, MA) for 10 minutes at room temperature.  The 
supernatant of each was filtered through a 0.22 µm SCFA filter (Corning Life Science, Corning, NY) and 
stored individually at 4 °C.  All lysates were then tested for alkaline phosphates activity using both pNPP 
and the APS-5 substrates. 
3.3.6 Bacterial Detection Using T7phoA 
Four separate overnight cultures of E. coli BL21 were serially diluted in LB to achieve 105, 104, 
103 and 102 CFU/mL. 900 µL of each dilution and a negative control of LB were placed in 15 × 100 mm 
test tubes, and mixed with 100 µL of 103 PFU/mL of T7phoA in LB.  Each combination, for each overnight 
culture, was performed in triplicate.  The samples were incubated at 37 °C with 200 rpm shaking for 6 
hours.  Samples were then passed through a 0.22 µm SCFA filter, stored at 4 °C, and alkaline 
phosphatase activity was determined using all three substrates.  
3.3.7 Determining Antibiotic Susceptibility of Bacterial Isolates Using T7phoA 
E. coli BL21 and BLT5403 were streaked onto the appropriate plates for single colonies.  A colony 
of each was selected using a sterile loop and inoculated into a test tube containing 900 µL of either LB or 
LB containing 100 µg/mL of ampicillin.  An un-inoculated test tube of LB was used as a negative control.  
All colony-antibiotics treatments were performed in triplicate.  The tubes were then incubated at 37 °C 
with 250 rpm shaking for 30 minutes.  Then 100 µL of 103 PFU/mL of T7phoA in LB was added to each 
tube.  The tubes were incubated under the same conditions for 3.5 hours.  For chemiluminescent 
detection a 50 µL samples of each tube was taken and mixed with 50 µL of the Phospha-Light™ 
substrate solution in a black 96-well plate and read as previously described.  For colorimetric detection a 
50 µL samples was mixed with 50 µL of the pNPP substrate and incubated for 1.5 hours at 37 °C in a 
clear 96-well plate.  The plate was then read for absorbance at 405 nm using the Synergy 2 reader.   
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3.3.8 Statistical Analysis 
Data was evaluated for statistically significance in Origin Pro version 9.0.0 (Northampton, MA).  
For both experiments looking at alkaline phosphatase overexpression versus a control, an unpaired one-
sided t-test, assuming unknown and unequal variances, with an alpha level of 0.05 was used to test for 
significance. This includes the initial phosphatase expression experiment, where the average signal-to-
noise ratio of all three T7phoA lysates was compared against that of T7control.  This was also done for the 
limit of detection experiment where the signal-to-noise ratio of each bacterial concentration level was 
compared to that of the control containing no cells. For the antibiotic resistance experiment the signal-
to-noise ratio was compared between the two treatments (with/without antibiotic) within each strain 
type using an unpaired two-sided t-test assuming unknown and unequal variances, with an alpha level 
of 0.05. In all figures error bars represent one standard deviation (SD) ± from the mean and a star (*) 
indicates a significant difference ( p < 0.05) between the compared sets of data.  
3.4 Results and Discussion 
3.4.1 Phage Construction 
To construct our alkaline phosphatase reporter phage, we designed a genetic construct carrying 
phoA (Figure 3.2a) for insertion in the T7 genome (Figure 3.2b).  T7 is a well-studied phage that broadly 
targets E. coli 65, and is used for phage-display  112.  Our genetic construct contains multiple components.  
Beginning from the 5’-terminus, we included the 1.3s biotin subunit from Propionibacterium shermanii 
transcarbonylase.  The T7 Select® cloning kits enables phage-display, allowing us to fuse the 1.3s subunit 
to 10B capsid protein of T7111.    The inclusion of this “biotin-tail” sequence has been shown to allow in 
vivo biotinylation of the fusion protein by E. coli 113.  At the 3’ end the 1.3s gene we incorporated a stop 
codon so that our alkaline phosphatase gene would not also be fused to the capsid, but rather free in 
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solution.  To enable T7 mediated expression of alkaline phosphatase we incorporated the T7 promoter 
and ribosome binding site sequences from the pET-3a plasmid (EMD Millipore).  Our synthetic phoA 
sequence was initially based on the E. coli sequence described by Change107.  This phoA gene is flanked 
on the 5’ by a His-tag/TEV cleavage site, and on the 3’ end by a 5× arginine tag. Finally we incorporated 
three restriction sites into our construct, EcoRI at the 5’ terminus, and SalI followed by HindIII at the 3’ 
terminus. The phoA coding sequence of the synthetic construct was codon optimized for expression 
within E. coli based on their proprietary algorithms. The full sequence of the construct can be found in 
the supplemental materials. We inserted our construct into T7 using the T7 Select®415-1 kit (Figure 
3.2c) and created a T7 control using the kit’s packing control DNA (Figure 3.2d).  PCR was used to screen 
and isolate phage plaques carrying our phoA construct and the control. 
3.4.2 Confirming ALP Overexpression 
The alkaline phosphatase gene phoA is endemic to E. coli107, and is typically expressed at low 
levels unless the cells are starved for phosphate114.  To confirm that T7phoA exhibits increased alkaline 
phosphatase production over background, and not due to the stress of the phage infection itself, we 
compared alkaline phosphatase activity in cells infected and lysed by our T7phoA and our T7control.  We 
added an aliquot of an overnight E.coli BL21 culture to fresh LB and incubated it for 3 hours to ensure 
the cells achieved logarithmic growth.  We then inoculated the cultures with either T7phoA or T7contorl, 
allowing the phage infection and replication cycle to occur two hours before testing the resulting lysates 
for phosphatase activity.  We tested for activity using both colorimetric pNPP (Figure 3.3a) and Lumigen-
APS 5 chemiluminescent substrate (Figure 3.3b).  There was a 10-fold signal-noise-ratio or greater 
difference in alkaline phosphatase activity between our control phage and our T7phoA, suggesting that 
infection of E. coli by our T7phoA does result in alkaline phosphatase overexpression.  Other research in 
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our lab has demonstrated the speificity of T7 phage-based detetion of E. coli in the presence of 
competitive bacterial species such as S. enterica, S. aureus, P. aeruginosa115.  
 
3.4.3 Bacterial Cell Limit of Detection Using T7phoA 
We incubated several concentrations of E. coli BL21, 105 to 102 CFU/mL, and a negative control 
of LB, with 102 PFU of T7phoA, for 6 hours at 37 °C.  We then filtered the samples to remove cells and 
tested for alkaline phosphatase activity using three substrates: pNPP, the Phospha-Light™, and Lumigen 
APS-5.  Significant alkaline phosphatase activity from initial bacterial levels of 104 CFU/mL and greater 
were detected using the colorimetric and chemiluminescent substrates (Figure 3.4).  It should be noted 
Figure 0.5 Confirming alkaline phosphatase expression.  Samples A1-3 are lysates form T7phoA, samples C1-3 are lysates from T7control. a) alkaline phosphatase signal with pNPP substrate, b) alkaline phosphatase signal with Lumigen APS-5 chemiluminescent substrate. 
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that the pNPP colorimetric assay required a 90 minute reaction time for the signal, resulting in a total 
assay time of 7.5 hours.  For comparison, the Phospha-Light™ method only required 10 minute 
incubation before testing.  The Lumigen APS-5 was read immediately following addition of the substrate, 
so does not significantly increase assay time.  Furthermore, with the Lumigen substrate we were able to 
detect an initial cell concentration of 103 CFU/mL (Figure 3.4c).   
 
The limit of detection (L.O.D.) of our scheme is driven by two factors. The first is the senstivity of 
the method used to detect alkaline phosphatase activity, as illustrated by the difference in L.O.D. of the 
colormetirc pNPP and the chemiluminescent Lumigen APS-5.  The second factor is the total number of 
cells infected, which impacts the total amount of alklaine phosphatase produced.  There is the potential 
to incorporate more sensitive detection methods for alklaine phosphatase to improve our limit of 
detection, for example the use of an electrochemical redoc-cycling scheme for alkaline phosphatase 
been shown to improve sensitivity32.  There is also the potential to incorporate a pre-enrichment step, 
commonly used in when testing food samples116, to increase bacterial levels prior to introduction of our 
T7phoA.  These options represent future areas of research to improve the sensitivity of this phage-based 
scheme. 
Figure 0.6 Limit of detection.  Signal to Noise Ratio of alkaline phosphatase activity after 6 hour incubation of initial concentrations of E. coli with 102 PFU/mL of T7phoA.  Substrates: a) pNPP; b) PhosphaLightTM; c) Lumigen APS-5. 
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3.4.4 Determining Antibiotic Susceptibility of E. coli Isolates 
Traditional tests for determining the antibiotic susceptibility of a bacterial isolate do so by 
looking for bacterial growth in the presence of the antibiotic117.  Broth microdilution Minimal Inhibitory 
Concentration (MIC) susceptibility testing in 96-well plates is a widely adopted method in clincal 
laboratories for assesing an isolates antibiotic susceptibility117.  The baterial inoculum is typically 
prepared from isolated colonies culutred on a non-selective agar plate for 18-24 hours117.  Several 
colonies, 3 to 5, are re-suspended in broth, standardized to a specific density, and then used innoculate 
wells containing varying concentrations of the antibiotic of interest117. The plates are then incubated for 
16-24 hours, depending on the baterial species, and anaylzed for growth117.  We were interested in 
determining if our phage-based probe had the potential to improve detection time of this later 
incubation step.  If a bacterial isolate were resistant to a given antibiotic it should grow in broth with and 
without antibiotic.  If we add T7phoA, we should see phage infection, phage replication, and the 
production of our alkaline phosphatase reporter in both treatments.  If the bacterial isolate were 
sensitive to a given antibiotic there will be bacterial death in the broth containing the antibiotic, 
resulting in no phage replication, and no alkaline phosphatase production. We should see therefore see 
a difference in alkaline phosphatase signal between the treatments.   
For a proof-of-principle application of our modified phage, we selected colonies of E. coli BL21, 
which is susceptible to ampicillin, and colonies of BLT5403, which carries a plasmid conferring resistance 
to ampicillin, and used them to inoculate either broth containing 100 µg/mL of ampicillin or broth not 
containing the antibiotic and incubated for them for 30 minutes.  T7phoA was then added and the 
samples were incubated for an additional 3.5 hours.  The samples were then analyzed for alkaline 
phosphatase activity using pNPP and Phospha-Light™ substrates (Figure 3 .5).  In our initial run, we had 
an overflow in pNPP absorbance readings for three samples - one of the BLT5402 colonies exposed to 
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ampicillin and two without - so for analysis we set the absorbance reading for those sample to be 
equivalent to the max read 405 nm absorbance for the run, which was 3.82.  We repeated the pNPP 
portion of the trial, the results are an average these two trials (Figure 3.5b).  For both substrates, there 
were no significant differences in signal between antibiotic treatments for E. coli strain BLT5403 strain, 
indicating that the strain was resistant to ampicillin.  There were significant differences in signal 
between the treatments for E. coli strain BL21, indicating that the strain was sensitive to ampicillin.  
Total assay time was < 4.2 hours using the chemiluminescent substrate, and < 6.5 hours using pNPP.  
These experiments suggest there incorporation of our phage-based assay in the second incubation step 
of the MIC susceptibility test could reduce the 16-24 hours delay for results117. While the colorimetric 
assay takes longer than the chemiluminescent one, for resource limited labs the pNPP assay does 
provide the ability for visual interpretation of results as can be seen in Figure 3.3c, which is a picture of 
the 96-well plate from the first pNPP trial. 
 
The increasing level of antimicrobial resistance among clinical and foodborne bacteria is a major 
public health concern driving the need for rapid diagnostics11.  The application of phage for the rapid 
detection of antimicrobial resistance is still in its infancy.  MicroPhage Inc. (Longmont, CO) had 
Figure 0.7 Detecting antibiotic resistance.  Signal to Noise Ratio of alkaline phosphatase activity from E. coli stains incubated with 102 PFU/mL of T7phoA in LB with and without ampicillin. Substrates: a) PhosphaLightTM; b) pNPP. c) Visual of wells with pNPP substrate. 
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developed an FDA approved phage-based lateral flow device for the rapid detection of methicillin 
resistant (MRSA) S. aureus82, though it is no longer commercial available83.  One of the challenges with 
lateral flow devices like that of MicroPhage’s, is that format does not lend itself to screening of a large 
number of samples.  Our T7phoA platform is readily leverage into 96-well microtiter plates, which are 
commonly used in for antibiotic testing117.  This format allows for the simultaneous analysis of a large 
number of samples and enables automation.  We believe this platform could be readily translated to 
phages with specificity to other bacteria which have public health relevance, as the bioengineering of 
phage has been readily be demonstrated56. Future research standardizing our bacterial inoculum 
procedure and demonstrating the robustness of our phage-mediate alkaline phosphatase-based 
platform for antibiotic resistance testing will be needed. 
3.4.5 Future Applications: Food and Water Testing 
Alkaline phosphatases are ubiquitously found among bateria, animal, and plants118 which 
introduces background noise for our phage-based scheme when applied to food and water samples.  
There a several methods which can be used to reduce this potential interferance.  Bacterial alkaline 
phosphatases are more heat stable than those of animal and plant origin, and researchers have shown 
the effective use of heat treatment step to differeniate bacterial alkaline phosphatases from those of 
both plant119 and animal origin120 when testing foods and could be implemented as part of our assay. 
Furthermore, we have designed several elements into T7phoA to address background noise in 
future experiments as we explore the applications of our proof-of-concept in real world testing. Our 
synthetic alkaline phosphatase contains both an N-terminus His-tag and C-terminus arginine tag (Figure 
3.2), both of which provide ways to selectively capture our reporter enzyme, and reduce background 
interference from endemic phosphatases in a sample. Our phage-based construct is also designed to 
enable bacterial separation.  We have incorporated a biotin tag fused to the capsid protein (Figure 3.2), 
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which allows us to attach our phage to magnetic beads coated with streptavidin, and then use these 
phage-magnetic beads for selective separation of E.coli cells from a sample.  Researchers have 
demonstrated the parity of phage-magnetic beads to immunomagnetic separation techniques121, and 
the succesfull application of these beads to selective separate a bacterial from water samples115.  These 
selective elements, on the both the enzyme and phage, can potentially be used solely or in tandem to 
help overcome a wide range of challenges from enzymatic inhibitors to endemic phosphatases to visual 
inteference of signal that are common when attempting to test food and water samples. 
3.5 Conclusion 
Phage-based diagnostics offer powerful platforms for the rapid detection of bacteria.  There has 
been an emphasis on using phage to detect low numbers of bacteria, but there are broader applications 
for phage-based diagnostics.  In applications where initial bacterial loads are high, like antibiotic testing 
or post-primary enrichment, phage-based detection can be quite rapid and specific. In these application, 
phage-based diagnostic are also attractive in comparison to PCR or immunological based methods as 
phage are cheaply produced, specific, and as we demonstrated, readily engineered to leverage a wide 
range of easy-to-use, commercially available detection platforms.   Another advantage to our scheme is 
that unlike immunological69 and PCR-based40 methods,  phage-based detection can distinguish between 
viable and non-viable cells, thus lowering the incidence of false positives. More research bioengineering 
flexible, phage-based reporters and demonstrating multiple forms of their applications is needed to 
illuminate the potential of phage-based detection and ensure its successful adoption in real world 
diagnostics to improve public health. 
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CHAPTER 4 PHAGE, PROTEASE, PEPTIDE: A NOVEL TRIFECTA ENABLING MULTIPLEX DETECTION OF VIABLE 
BACTERIAL PATHOGENS 
4.1 Abstract 
Bacteriophages represent rapid, readily targeted, and easily produced molecular probes for the 
detection of bacterial pathogens.  Molecular biology techniques have allowed researchers to make 
significant advances in the bioengineering of bacteriophage to further improve speed and sensitivity of 
detection.  Despite their host-specificity, bacteriophages have not been meaningfully leveraged in 
multiplex detection of bacterial pathogens.  We propose a proof-of-principal phage-based scheme to 
enable multiplex detection.   Our scheme involves bioengineering bacteriophage to carry a gene for a 
specific protease, which is expressed during infection of the target cell.  Upon lysis, the protease is 
released to cleave a reporter peptide, and the signal detected.  Here we demonstrate the successful: i) 
modification of T7 bacteriophage to carry TEV protease; ii) expression of TEV protease by E. coli 
following infection by our modified T7, an average of 2000 units of protease per phage are produced 
during infection; and iii) proof-of-principle detection of E. coli in 3 hours after a primary enrichment via 
TEV protease activity using a fluorescent peptide and using a designed target peptide for MALDI-TOF MS 
analysis.  This proof-of-principle can be translated to other phage-protease-peptide combinations to 
enable multiplex bacterial detection, and readily adopted on multiple platforms, like MALDI-TOF MS or 
fluorescent readers, commonly found in labs. 
4.2 Introduction 
There has been a renewed interest in the application of bacteriophages (phages) for the 
detection and control of bacterial pathogens.  In the area of diagnostics,  phages are attractive as 
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detection elements due to their relative ease of production, host specificity, and potential for rapid 
signal amplification 54.   Furthermore, in comparison to immunological 69 and PCR-based 40 detection 
methods, phage-based detection schemes can distinguish between viable and non-viable cells, as viable 
cells are required for phage proliferation 122. This potentially means that phage-based diagnostics could 
have lower incidences of false positives. Several phage-based diagnostics have already entered the 
commercial market. Biomérieux (St. Louis, MO) has a product line called VIDAS® UP which leverages 
phage components for the detection of Salmonella, Listeria, and E. coli O157.  Sample6 (Cambridge, MA) 
uses a phage-delivered luciferase reporter for the detection of environmental Listeria. 
Individual testing for multiple pathogens requires large sample sizes, numerous selective media 
and reagents, and a significant amount of time and technician labor.  Multiplex methods, which use a 
single reaction sample to test for multiple pathogens, are attractive due to their reduced complexity and 
time to result.  The majority of multiplex systems leverage DNA 123 or immunological 124 based methods, 
and thus face the potential false positive issues due to the presence of dead cells.  There has been 
limited research in applying phage in multiplex detection schemes. Work by 125 coupled phage 
amplification with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis 
(MALDI-TOF MS) for the simultaneous detection of E. coli and Salmonella, but the majority of 
bioengineered phage-based detection schemes have leveraged enzymatic reporters, like luciferase, that 
do not lend themselves readily to a single sample multiplex format 54, 103, 126.   
We propose a novel phage-based platform to enable multiplex detection of bacteria using phage 
bioengineered to carry genes encoding highly specific proteases, whose activity is detected by the 
cleavage of specific peptides (Figure 4.1).  The phage provides specificity for a viable bacterial target, 
and the protease-peptide pair provides further specificity and lays the groundwork for single sample 
multiplex detection.  For our proof-of-principle, we genetically engineered T7, a phage with broad 
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specificity for E. coli 65, to carry a gene for a protease from tobacco etch virus (TEV).  TEV protease is a 
highly specific protease recognizing the amino acid sequence ENLYFQ(G/S), with cleavage between the 
Q and G or S amino acids 127.  The cleavage event, indicative of the presence of TEV protease produced 
by a viable E. coli cells following infection with the engineered T7, can be detected using various 
platforms. Our work demonstrates the successful: i) modification of T7 bacteriophage to carry TEV 
protease gene; ii) expression of TEV protease by E. coli following T7 infection; and iii) detection of E. coli 
in sample via TEV protease activity.  To show that this scheme was applicable to multiple platforms, we 
detected protease activity two ways. First, using a common fluorescent plate reader to detect the signal 
from a cleaved beacon peptide; and second, using MALDI-TOF MS to detect the production of a reporter 
peptide produced by the cleavage of a designed larger peptide.   Both of these platforms are not only 
sensitive, but have the capability for high-throughput, multiplex screening of samples.  We believe this 
scheme has the potential to be readily converted to other phage-protease-peptide combinations to 
enable multiplex detection of bacterial pathogens within a sample. 
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Figure 0.8 Phage-Protease-Peptide Multiplex Detection Scheme.  (a) Phage specific to a bacterial target, is bioengineered to carry a gene for a specific protease.  Protease acts on a specific peptide resulting in a unique fluorescent signal or peptide product. (b) Phage and corresponding peptides are added to a single sample.  Signal is produced only if corresponding bacterial target is present in sample to produce the protease. 
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4.3 Materials and Methods 
4.3.1 Bacterial Strains, Bacteriophage Strains, Media Culture, and Enumeration 
Both the bacterial strain E. coli BL21 and the bacteriophage T7 (T7Select® 415-1) were 
purchased from EMD Millipore (Billerica, Massachusetts).  All overnight cultures of E. coli BL21 were 
grown in 150 mL flasks containing 35 mL of Luria Broth (LB), pH 7.5, incubated at 37 °C with shaking at 
200 RPM.  The overnight cultures were serially diluted and spread plated on LB agar to confirm bacterial 
concentration for subsequent experiments.    The titer of samples containing T7 bacteriophage were 
determined following the double agar overlay plaque assay on LB agar as commonly described 110. 
4.3.2 Construction and Isolation of Engineered Bacteriophage 
Using standard molecular techniques, we engineered T7 bacteriophage to carry the TEV 
protease gene for overexpression within E. coli. We designed a gene cassette (Figure 4.2) to enable T7-
induced expression of TEV protease in E. coli, and had the cassette synthesized within a pUC57 plasmid 
by GenScript USA Inc. (Piscataway, NJ). The TEV protease cassette was amplified with the iProof high-
fidelity PCR kit (Bio-Rad Laboratories, Hercules, CA) using standard M13 forward and reverse primers.  
The PCR product was purified using QIAquick PCR Purification Kit (Qiagen, Valencia, CA), and then 
digested with restriction enzymes EcoRI and HindIII, both purchased from New England Biolabs (Ipswich, 
MA).  The digested construct was then inserted into the T7 Select® 415-1 genome using T4 DNA ligase 
(Promega, Madison, WI) and packaged using the T7 Select® cloning kit (EMD Millipore) to create T7tev 
(Figure 4.2). In parallel, we used the T7 Select® kit’s control DNA insert, which encodes for the S•TagTM, 
to create T7control (Figure 4.2), a control phage which would not induce TEV protease expression.  Both 
T7tev and T7control packaging reactions were propagated following the T7 Select® kit’s protocol and plated.  
Individual plaques were picked off plates using a sterile loop, dipped into 100 µL of LB, and stored at 4 
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°C. The isolated plaques were screened with the iProof PCR kit for the appropriate size insert using the 
T7Select® Up and Down primers included in the cloning kit.  Isolated plaques containing the appropriate 
sized insert were propagated on E. coli BL21, and the subsequent lysates screened to confirm the 
presence of the insert.  These lysates were passed through a 0.22 µm SCFA filter (Corning Life Science, 
Corning, NY), stored at 4 °C, titered, and used as the stock bacteriophage for subsequent experiments. 
4.3.3 Fluorescent Detection and Quantification of TEV Protease 
Fluorescent detection of TEV protease activity was performed using the SensoLyte® 520 TEV 
Activity Assay Kit (AnaSpec, Inc., San Jose, CA).  50 µL of sample was mixed with 50 µL of substrate in a 
96-well plate, incubated at 30 °C, and read every 10 minutes, over 90 minutes, using the Synergy 2 plate 
reader (BioTek Instruments, Inc., Winooski, VT) with Ex/Em filters 485/528 nm. For quantification of TEV 
protease in a sample, a standard curve was run using the TEV protease standards provided with the 
SensoLyte® kit. Our TEV samples were in LB and the provided standards were in the kit’s buffer, which 
meant the standards and our samples had a different base background noise.  To account for this we 
compared Vmax, calculated using the Gen5 software (Biotek Instruments, Inc., Winooski, VT), of the 
Figure 0.9 Diagram of DNA Constructs. (a) Our designed TEV protease gene cassette. (b) Genome of T7 Select® 415-1 indicating 10B capsid protein and insertion site. (c) Genome of T7tev with the insertion of our gene cassette. (d) Genome of T7control with insertion of the S•TagTM control. 
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fluorescence over 90 minutes between our samples and the standards to quantify the amount of TEV 
protease present. 
4.3.4 Characterizing TEV Protease Production 
An overnight culture of E. coli BL21, prepared as previously described, was serially diluted in LB 
to achieve 109, 108, 107 and 106 CFU/mL. 900 µL of each dilution and a negative control of LB were 
placed in 15 x 100 mm test tubes, and mixed with 100 µL of 103 PFU/mL of T7tev in LB.  Each combination 
was performed in triplicate.  The samples were incubated at 37 °C with 200 rpm shaking for 3 hours.  
Samples were then passed through a 0.22 µm SCFA filter (Corning Life Science, Corning, NY), stored at 4 
°C, tittered, and TEV protease activity fluorescently determined as previously described.  The 
experiment was repeated with two separate overnight cultures to achieve biological triplicates. 
4.3.5 Target Peptide Design and MALDI-TOF Mass Spectrometry Analysis 
We designed two 26 amino acid peptides, TEV-L and REF-L (Table 1), to detect TEV protease 
activity using MALDI-TOF MS.  TEV-L was designed to contain the TEV protease cleavage site, and when 
cleaved by TEV protease to produce two identical 13 amino acid peptides, TEV-S (Table 4.1).  The REF-L 
(Table 4.1) peptide was used as an internal reference. Samples of both TEV-L and REF-L were 
synthesized by Biopeptide Co., Inc. (San Diegeo, CA), at 98% purity.  Samples were reconstituted in 
sterile water to make a 1 mM stock solution.   
Reagents for MALDI-TOF MS analysis are as follows:  triflouroacetic acid (TFA), α -cyano-
hydroxycinnamic acid (α-CHCA), and Tetrahydrofuran (THF).  TFA and α-CHCA were purchased from 
Sigma-Aldrich (St. Louis, MO), and THF was purchased from Fisher Scientific (Pittsburgh, PA). For MALDI-
TOF MS analysis, 5 µL of a matrix solution (0.16 M α-CHCA in 69: 30: 1% THF/H2O/TFA) was mixed with 5 
µL of a sample.  2 µL of the matrix/sample mixture was then spotted onto a stainless steel target and the 
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solvent was allowed to evaporate at room temperature.  Analysis was performed using a Bruker 
Autoflex III smartbeam time-of-flight mass spectrometer (Bruker Daltonics, Inc., Billerica, MA). All 
spectra presented were obtained in reflectron mode and represent an average of 5000 shots acquired at 
46% laser power. 
Table 0.2 Peptides Deigned for MALDI-TOF detection of TEV Protease Activity 
Name Amino Acid Sequence Residue Number Molecular Weight 
TEV-L SHFLKKRENLYFQ#SHFLKKRENLYFQ1 26 3401.93 g/mol TEV-S SHFLKKRENLYFQ 13 1709.95 g/mol REF-L GPHFLKKRETLFQ#GPHFLKKRETLFQ2 26 3183.72 g/mol REF-S GPHFLKKRETLFQ 13 1600.87 g/mol 
1Bold letters designate the recognition sequence for TEV Protease, the hashtag indicates the cleavage 
site. 2Bold letters designate the recognition sequence for HRV-3C Protease, the hashtag indicates the 
cleavage site 
4.3.6 Detection of E. coli Through TEV Protease Activity Using Fluorescence and MALDI-TOF MS 
Three colonies of E. coli BL21 streaked out onto an LB agar plate were selected, each put into 35 
mL of LB in a 150 mL flask,  and incubated at 37 °C with shaking at 200 rpm for 16 hours to simulate a 
primary enrichment. 150 µL of this primary enrichment was added to 35 mL of fresh LB in a 150 mL flask 
and incubated for 3 hours under the same conditions.  Then 10 µL of T7tev phage stock (1.08 x 1011 
PFU/mL) was added and the sample incubated for another two hours under the same conditions.   LB 
inoculated with 10 µL of T7tev stock was used as a control.  The resulting lysates were then filtered with a 
0.22 µM filter to remove any cellular debris.  Each lysate was analyzed in triplicate for TEV protease 
activity using the SensoLyte® fluorescent assay as previously described.  For MALDI-TOF MS analysis 12.5 
µL of each lysate was mixed with 12.5 µL of solution containing 10 µM of TEV-L and REF-L peptides in 
TEV reaction buffer from the SensoLyte® kit.  Samples were incubated for 1 hour at 30 °C, heated to 80 
°C for 10 minutes to deactivate any TEV present, and then cooled to 4 °C until MALDI-TOF MS analysis. 
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4.4 Results 
4.4.1 Constructing a TEV Protease Producing Bacteriophage 
To create our proof-of-principle phage-based enzymatic multiplex detection of bacteria, we 
designed a gene cassette containing a gene for TEV protease (Figure 4.2a) for insertion in the T7 genome 
(Figure 4.2b), a phage with broad host range specificity for E. coli 65  We built upon a TEV protease 
mutant S219V which was shown to be more stable and catalytically efficient than the wild type when 
expressed in E. coli 127. The S219V TEV protease gene is linked to a maltose binding protein (MBP) at the 
N-terminus by a short amino acid sequence containing the TEV cleavage site sequence, ENLYFQG, 
followed by a 6X His-tag.  At the C-terminus there is a 5X arginine tag. The MBP chaperone and ability of 
the protease to self-cleave from the chaperone was shown to increase solubility and activity of the 
protease when expressed in E. coli 128  Upstream of the start codon for MBP, we added the T7 promoter 
sequence and ribosome binding site sequence from the pET-3a plasmid (EMD Millipore), to allow for T7-
mediated overexpression of the protease.  The T7 Select® cloning kits are designed to enable phage-
display, and the inserted peptide sequence is fused to 10B capsid protein of T7 111  We wanted the 
protease to be free in solution, not attached to the phage capsid, so we followed the example of 129,  
and added a stop codon in all three reading frames upstream of our T7 promoter.  Lastly, we added the 
restriction site for EcoRI at the 5’ terminus of our cassette and the HindIII site at the 3’ terminus.  We 
removed a HindIII site found within the TEV protease gene. Our gene cassette was synthesized by 
Genscript, Inc., and the codon sequences optimized using their proprietary OptimumGene™ algorithm 
for expression within E. coli. The full sequence of our cassette can be found in via Genbank, accession 
number KT183030. We cloned our cassette into the T7 Select®415-1 genome (Figure 4.2c) and as a 
control cloned the T7 Select® kit’s control insert, encoding the S•TagTM (Figure 4.2d).   
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After cloning both inserts, we used PCR to screen plaques for phage that contained either our 
gene cassette or the control insert.  We choose two plaques, 15 and 41, carrying our gene cassette and 
one plaque carrying the control insert, to look for TEV protease activity.  We propagated the plaques in a 
broth of E. coli, and after incubation filtered the lysates to remove any remaining cells. We took samples 
of each of the three lysates and tested for TEV protease activity using the SensoLyte® fluorescent TEV 
assay.  We monitored fluorescence over 90 minutes, and divided the signal by the signal of a known 
negative control, a sample containing only LB and the fluorescent peptide substrate (Figure 4.3).   After 
90 minutes, we could clearly observe an increase in fluorescence vs. the negative control in both phage 
samples carrying the TEV gene cassette and did not observe an increase in fluorescence in the phage 
sample carrying the control insert.  We thus show that not only have we successfully introduced our TEV 
protease gene cassette in T7, but that the protease is produced in an active form by E. coli following 
infection by our T7tev.  For all further experiments, we used T7tev phage derived from our plaque 15 
lysate. 
Figure 0.10 Confirming TEV protease product.  Ratio of fluorescent signal in lysate samples to that in an LB negative control over time.  Plaque 15 and 41 are phage confirmed by PCR to carry the TEV protease gene cassette, Plaque C1 carries the S•TagTM insert. 
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4.4.2 Characterizing TEV Protease Production 
In order to understand how much TEV protease was being produced and how many E. coli cells 
were needed to obtain a signal, we incubated several concentrations of E. coli BLS21, 109 to 106 cfu/mL, 
and a negative control of LB, with 102 PFU of T7tev, for three hours at 37 °C.  We then filtered the 
samples and monitored fluorescence over 90 minutes, and normalized the signal to the negative control 
(Figure 4.4).  We observed an increase in fluorescence vs. the negative control after 90 minutes in 
samples with a starting CFU/mL of 107 and 108, but observed no increase in the others.   
Using the TEV protease standards provided with SensoLyte® assay we determined the amount 
of protease produced in the 107 and 108 CFU/mL samples to be 400 ± 300 ng of TEV/mL and 1500 ± 500 
ng of TEV/mL, respectively (data not shown).  TEV protease is a 25 kDa protein 127, and using its 
molecular weight we can calculate the number of TEV protease molecules present per mL in these two 
Figure 0.11 TEV protease activity from varying starting cell concentrations.  Ratio of fluorescent signal in T7tev lysates (with starting cell concentrations of 106, 107, 108, and 109 CFU/mL) to that of a control with no cells, over time. 
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samples to be 1013.0 and 1013.6, respectively.   The final phage titer of the 107 and 108 samples was 
determined to be 109.86 ± .06 and 1010.17 ± .13 PFU/mL, respectively. Dividing the average number of 
molecules of TEV protease produced by the average amount of phage produced, results in approximate 
values of 1380 and 2754 in the 107 and 108 samples, indicating that roughly 2000 molecules of TEV 
protease are produced for every phage produced by an infected E. coli BL21 cell. 
4.4.3 Designing Peptides for MALDI-TOF 
MALDI-TOF mass spectrometry can detect small peptides with a relative molecular mass of 
~1000-3000  at sample concentrations as low as 1 nM, though as the complexity of the sample matrix 
increases the sensitivity typically decreases to > 1 µM of target peptide 130.  We designed two peptides, 
TEV-L and REF-L (Table 4.1), for detection by MALDI-TOF MS.  TEV-L was designed so that when cleaved 
by TEV protease it would produce two identical peptides, TEV-S (Table 4.1).  This provided us with two 
advantages: first, a doubling in signal would be expected as for every cleavage of TEV-L we would get 
two TEV-S peptides; and second, increased specificity would be present since cleavage of TEV-L by a 
protease other than TEV would likely not result in the production of two identical smaller peptides. 
4.4.4 Detection of E. coli Through TEV Protease Activity Using Fluorescence and MALDI-TOF 
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For a proof-of-principle, we used a culture of E. coli BL21grown from a single colony for 16 hours 
in LB as a stand in for a non-specific primary enrichment typically used for the detection of food borne 
pathogens, like E. coli O157:H7 and Salmonella spp. 131.  We took a portion of this primary enrichment 
and inoculated fresh LB, incubated for 3 hours, then added our T7tev, and incubated another 2 hours.  
The samples were filtered to remove any remaining bacterial cells, and then analyzed for TEV protease 
activity using the fluorescent kit (Figure 4.5) and MALDI-TOF MS (Figure 4.6).  Both methods were able 
to detect TEV protease activity in the samples containing E. coli.  In the majority of the E. coli positive 
samples, MALDI-TOF MS analysis could not detect any remaining TEV-L, whereas a TEV-S peak was 
always observed. 
Figure 0.12 Fluorescent detection of E. coli via T7-induced TEV protease activity. Fluorescent signal intensity of E.coli positive samples and a negative (Control) over time. 
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4.5 Discussion 
In this work we demonstrate the production of a highly specific protease delivered by an 
engineered phage for the detection of E. coli using fluorescent and MALDI-TOF MS platforms.  While the 
bioengineering of reporter phage is not new 54, 56, 103, to our knowledge we are the first to demonstrate 
the use of a protease as a reporter with application in multiple detection platforms.  While our proof-of-
principle is specific for E. coli, we believe our scheme can be readily modified for the detection of other 
bacterial species in combination with other specific proteases.  Successful bioengineering  of phage 
specific for other species, like Salmonella and Listeria, has been well demonstrated 56.  The successful 
Figure 0.13 MALDI-TOF detection of E. coli via T7-induced TEV protease activity.  Spectra of representative E.coli positive sample (a) and negative control (b).  The peaks corresponding to TEV-L, TEV-S, and REF-L are labeled. 
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expression of viral proteases in gram negative bacteria, like E. coli, has also been demonstrated 132-134. 
This phage-protease-peptide combination lays the groundwork for a novel multiplex detection scheme 
of various bacteria within a sample. 
Of the two platforms we leveraged for the detection of E. coli via phage-induced TEV protease 
activity, fluorescence is likely the most widely adoptable.  Fluorescent/luminescent readers, both high-
throughput, like SynergyTM 2 (BioTek) or GloMax® (Promega), and smaller mobile readers, like the 
QuantusTM Fluorometer (Promega) are commercially available and commonly used. There is also a wide 
range of fluorescent/quencher markers for substrate-based protease probes 135, 136 suggesting that a 
mature phage-protease-fluorescent peptide multiplex scheme could be easily implemented by many 
laboratories.   
The upfront equipment cost necessary for a MALDI-TOF MS system may be higher than that of a 
fluorescent system, but the cost is lowering to that point that when combined with the low cost and 
high speed of sample analysis, MALDI-TOF systems are beginning to be adopted in high and low 
resource countries 137-139.  MALDI-TOF MS analysis offers several advantages for our detection scheme.  
The first is the higher resolving power of MALDI-TOF MS over fluorescence.  MALDI-TOF MS 
differentiates small peptides based on their mass-to-charge (m/z) ratios, and they need only differ by a 
couple m/z units to be easily distinguished. One could readily design a very wide range of peptides for 
detection, and thus the breadth of the multiplexing capability is much greater with MALDI-TOF MS. To 
expand the breadth of multiplexing with a fluorescent readout, one would need to incorporate more 
and more fluorescent molecules whose emission spectra may not be resolved well. The second 
advantage MALDI-TOF MS offers is specificity.  There is the possibility that a given sample may contain 
an extraneous protease that cleaves our peptide, producing a signal in our fluorescent scheme, resulting 
in a false positive. The TEV-L peptide is designed to be cleaved into two identical peptides, TEV-S, by TEV 
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protease.  It is unlikely that the activity of another protease would result in peptides whose m/z ratio 
would be identical to TEV-S.  Thus, using the MALDI-TOF MS platform we can be further assured that the 
signal we measure is only due to TEV protease activity, which would only be present if viable E. coli, 
infected by T7tev, were present in the original sample.  A third advantage to the MALDI-TOF MS platform 
is the signal amplification inherent in our scheme, where TEV protease cleavage of the TEV-L peptide 
results in two TEV-S peptides.  This can be observed by comparing the signal TEV-L to REF-L in the 
control to the signal of TEV-S to REF-L in the E. coli positive samples (Figure 4.6).  There is the potential 
that this signal amplification and the sensitivity of the MALDI-TOF MS could improve the bacterial limit 
of detection beyond that of the fluorescent scheme, which is approximately 107 CFU/mL (Figure 4.4).  
Further work determining the limit of detection for the peptides, optimizing the sample matrix for both 
TEV activity and background signal,  and the use of sample enrichment tools that can be readily coupled 
with MALDI, like Surface-Enhanced Laser Desorption/Ionization 140, need to be explored before 
understanding if this benefit can be realized.   
PCR-based detections methods have clearly demonstrated their sensitivity, though DNA 
contamination remains a challenge.  Coupling PCR with a sample pre-treatment of ethidium bromide 
monoazide or propidium monoazide, dyes that irreversible bind DNA, has been shown to enable PCR-
based differentiation of viable and non-viable cells 141-143.  Studies, however, suggest more research is 
needed to optimize the successful use of these dyes. When used at low concentrations, interfering 
compounds or high levels of non-viable cells, both of which may be found in environmental or foods 
samples, can still result in false positive 144, 145.  At high concentrations, these dyes are toxic, expensive, 
and have been shown to have a negative effect on the detection of DNA from viable cells of clinical 
important pathogens 145-147.  It therefore seems prudent to further probe the capabilities and potential 
applications of phage-based detection of viable bacterial cells. 
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A challenge for phage-based bacterial detection is the condition of the target cell.  
Environmental conditions, temperature, bacterial growth rate, membrane composition, and cell injury 
are all factors that have been shown to impact the success of phage infection and subsequent 
productivity of infection 122.  This is a key reason we focused on bacterial detection following primary 
enrichment, to ensure the cells were in a state favorable for infection.  In fact, when we looked for TEV 
activity in samples containing 109 CFU/mL, we could detect none (Figure 4.4). This likely occurs because 
at a concentration of 109 CFU/mL the majority of E. coli cells are in stationary rather than log phase, thus 
significantly limiting cell growth and phage replication.  To address this upper limit, we added a step 
where a portion of the primary enrichment sample was added to fresh both and incubated to allow the 
cells to re-enter log phase before the addition of phage. Another reason for a primary enrichment is that 
the level of a pathogenic bacteria in a sample like food can be quite low, and the sample sizes needed to 
detect their presence are large enough, 25 g to 375 g 131, to make detection without an enrichment step 
unfeasible.  A study by 116 found that injured pathogenic bacteria only grew to levels between 104.0 to 
108.3 CFU/mL when revived in pre-enrichment broth after 24 hours.   A study by 148, using SEL broth 149, 
found that injured pathogenic cells of E. coli, Salmonella, and Listeria reached levels > 109 CFU/mL after 
a 20 hour enrichment. These studies further highlight the need for the appropriate enrichment 
conditions to ensure bacterial and successful detection.  In future work we intended to implement a 
concentration step, either filtration based or using phage-based magnetic bead separation 115 following 
appropriate primary enrichment conditions to ensure that necessary cell concentrations are consistently 
achieved. 
4.6 Conclusion 
In summary, bioengineering of bacteriophage offers novel platforms for the specific and 
sensitive multiplex detection of bacterial pathogens within a sample.  By utilizing molecular reporters 
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with multiple modes of detection, one can adapt a base technology, in this case phage-based enzymatic 
reporters, to meet the varying capabilities of laboratories around the world.  To further explore this 
multi-platform approach to detection, our lab is also designing a paper-fluidic, immuno-lateral flow 
assay for maltose binding protein, a by-product of our T7-mediated overexpression of TEV protease, as 
an alternative detection method for the presence of E. col that can be performed in resource-limited 
environments, like on-farm. Continued research and novel phage constructs will further expand the 
application and use of phage-based diagnostics for bacterial detection in the real world. 
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CHAPTER 5 BIOENGINEERING BACTERIOPHAGE TO ENHANCE SENSITIVITY OF PHAGE AMPLIFICATION-BASED 
PAPER FLUIDIC DETECTION OF BACTERIA 
5.1 Abstract 
Bacteriophage (phage) amplification is an attractive method for bacterial detection due to 
phage-host specificity, short amplification time, and its ability to differentiate between viable and non-
viable cells.  Modern molecular techniques have further enabled the bioengineering of phages to co-
produce reporter molecules, such as peptides and enzymes, thus increasing the sensitivity of phage 
amplification-based detection.   The outcome of these advances is an array of targeted bacterial 
detection probes that are easily produced.  The next step is leveraging bioengineered phage to create 
cheaper, faster, and easier to use detection platforms.  Paper fluidic devices, like the lateral flow assay, 
are ideal testing platforms due to their low cost of production, simplicity, portability, and reliability.  Our 
work investigates the use of bioengineered T7 phage strains to increase the sensitivity of phage 
amplification-based lateral flow assays.  In this work we demonstrate a greater than 10-fold increase in 
sensitivity using a phage-based peptide reporter, maltose-binding protein, over the detection of T7 
phage virion itself, and a greater then 100-fold increase in sensitivity using the a phage-based enzymatic 
reporter, alkaline phosphatase.  This increase in sensitivity enabled us to detect 103 CFU/mL of E. coli in 
broth after 7 hours, and by adding a filter concentration step, the ability to detect a regulatory relevant 
E. coli concentration of 100 CFU/100 mL in artificially contaminated river water after 9 hours. The 
combination of the paper fluidic format with phage-based detection provides a platform for the 
development of novel bacterial diagnostics that are sensitive, rapid, and simple to use. 
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5.2 Introduction 
The application of bacteriophage (phage) as detection probes has many advantages. 
Phages are relatively ease to produce, they are host specific, can potential distinguish between 
viable and non-viable cells, and their use allows for rapid signal amplification54. The use of 
phages for signal amplification is commonly referred to as phage amplification. In concept, a 
single phage adsorbs to and infects a single bacterial cell.  The phage DNA is injected into the 
host, and through a series of mechanisms, it essentially high-jacks the metabolic machinery of 
the cell into the production of new phage.  At the appropriate point in the infection cycle 
lysozyme is produced, rupturing the cell, and releasing tens to thousands of new phage into the 
environment, an increase that can be detected through traditional plating methods such as a 
plaque assay or other detections scheme like ELISA.  For a phage such as T7, which has broad 
range specificity for E. coli, time from infection to lysis occurs in as little as 25 minutes65, after 
which over 100 infectious particles (i.e. new phages) are released66.  Therefore, in the time it 
would take an E. coli cell to double67, there is a potential 100-fold increase in T7 phage, making it 
an attractive component in a detection scheme for E. coli.   
Advances in bioengineering have allowed the genetic modification of phages to co-
express reporter peptides and enzymes during host cell infection, further enhancing the 
magnitude and speed of signal amplification54, 70, 73, 75.  Both modified and unmodified phage 
amplification schemes have been leveraged in bacterial detection methods126, but little research 
has attempted to combine phage amplification with a resource-limited amenable platform, such 
as lateral flow assays (LFA). Paper-fluidic16, 17 and microfluidic18, 19 based devices, like LFAs, are 
attractive testing platforms due to their ease-of-use, cost, and reliability.  They have been shown 
to be effective platforms for the detection of analytes and pathogens of interest in low-resource 
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settings14. The simplicity and ubiquity of the home pregnancy test highlights the attractiveness 
of the LFA, particularly when testing liquid matrices. 
LFAs for the detection of pathogenic strains of Escherichia coli have previously been 
investigated22, 23, and there are commercially available products for some E. coli strains such as 
the DuPont™ Lateral Flow System for E. coli O157:H7 (DuPont, Wilmington, DE) and Neogen’s 
Reveal 2.0 for E. coli O157:H7 (Neogen, Ann Harbor, MI). The challenge with these immuno-
based lateral flow assays is the difficulty in developing a mixture of antibodies with a broad 
enough range to capture an entire species of bacteria, such as the generic E. coli, which is 
commonly used as indicator of water quality 36, and a marker of urinary tract infections150. These 
LFAs also require a heat inactivation step, indicating that these assays actually detect non-viable 
rather than viable cells.  If the original sample has high levels of heat-killed cells, perhaps due to 
a validated pathogen reduction step, the test could result in a false positive.  Furthermore, many 
of these LFAs require an enrichment of 8-24 hours prior to testing. Phages offer potential 
solutions to challenges.  Phage strain selection offers the ability to narrow or broaden the 
bacterial specificity of the test.  Phage can only amplify in the presence of viable cells, thus 
reducing the potential of false positives, and the dynamics of phage amplification could 
conceivably enhance detection time. 
In previous work, our lab bioengineered two reporter T7 phage strains: i) T7TEV which 
carries a gene for tobacco etch virus (TEV) protease that is expressed upon infection of E. coli 151; 
and ii) T7ALP, which carries the E. coli alkaline phosphatase gene that is overexpressed during 
infection152. A co-product of T7TEV infection is maltose-binding protein (MBP), which acts as a 
chaperon for the folding of TEV protease before being cleaved from the construct128.  
Approximately 2000 units of TEV protease, and concurrently molecules of MBP, are produced 
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per phage during infection151. Given that T7 has a burst size of ~100 PFU per cell, there is a 
potential production of 200,000 MBP molecules per bacterial host.  MBP is also used as a protein 
capture tag in purification schemes, so commercial antibodies are widely available, making the 
construction of an LFA for MBP quite pragmatic.  Alkaline phosphate is a commonly used 
enzymatic reporter118, with readily available commercial antibodies against it as well.  
Furthermore, when paired with a colorimetric substrate like 5-bromo-4-chloro-3'-
indolyphosphate and nitro-blue tetrazolium (BCIP/NBT), alkaline phosphatase can act as its own 
reporter, thus eliminating the need for a secondary reporter antibody and simplifying the 
standard sandwich LFA scheme. Both bioengineered T7 reporters: MBP due to its level of 
expression per cell; and alkaline phosphatase due to its enzymatic activity; make attractive 
targets for an LFA with the potential to improve sensitivity in a phage amplification-based 
detection scheme. 
 Our study is composed of three parts. The first investigates the dynamics between initial 
T7 phage inoculum concentrations and E. coli concentrations on subsequent phage amplification 
over time, providing us with an understanding of the level of phage amplification we can 
reasonable expect from a given starting concentration of cells.  The second part focuses on 
whether bioengineered phage can enhance the sensitivity of phage amplification-based LFAs.  
We develop and compare three LFAs targeting different reporter products from phage-
amplification schemes: i) the wild-type T7 phage virion itself; ii) a MBP reporter produced by a 
bioengineered T7 phage; and iii) an alkaline phosphatase reporter that is delivered by a 
bioengineered T7 phage. Lastly, we investigate whether or not an increase in LFA sensitivity 
translates into increased sensitivity for bacterial detection.  To do this we demonstrate a proof-
of-principle application of our phage amplification-based lateral flow assay scheme for the 
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detection of low levels of E. coli in media and river water. We demonstrate the ability of 
bioengineered phage-based reporters to improve the sensitivity of phage amplification-based 
LFA detection schemes several orders of magnitude, thus enabling the rapid detection of a low 
bacterial concentrations in artificially contaminated broth and river water.  Our research 
highlights the potential of bioengineered phage-based reporters in LFAs targeted to bacterial, 
and we believe further research in this area can lead to the development of rapid, sensitive, and 
cheap diagnostics assays for bacterial detection. 
5.3 Materials and Methods 
5.3.1 Bacteriophage Strains, Working Stock Preparation 
E. coli BL21 stock was purchased from EMD Millipore (Billerica, Massachusetts) and wild-
type bacteriophage T7 stock was purchased from ATCC (BAA-1025-B2, Manassas, Virginia). E. coli 
BL21 culture was routinely grown overnight in 50 mL of Luria Broth (LB), pH 7.5, at 37 °C with 
250 rpm shaking.  An overnight culture (1 mL) was then added to 200 mL of fresh LB and 
incubated at 37 °C with shaking until an optical density (OD) of at least 0.6 at 600 nm was 
reached, typically after 3.5 hours.  Then 20 µL of T7 stock was added to the E. coli BL21 culture 
and allowed to incubate, with shaking, at 37 °C for 1.5 hours.  NaCl (5g) was added to the 200 mL 
culture to prevent further phage adsorption to the cells.  The culture was then divided into six 35 
mL tubes and spun at 7598 X g on a Fiberlite F21-8x50y fixed angle rotor (ThermoFisher 
Scientific, Waltham, MA) for 10 minutes at room temperature.  Supernatant was collected and 
filtered through 0.22 µm SCFA filter (Corning Life Science, Corning, NY). 40 mL of this filtered 
culture was divided into four 13.5 mL ultracentrifuge tubes and spun at 105644 X g for 2 hours 
on a Fiberlite F65L-6X13.5 fixed angle rotor (ThermoFisher Scientific) at room temperature. The 
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supernatant was removed and pellets in each tube were re-suspended in 1 mL of 25 mM 2-(N-
morpholino)ethanesulfonic acid (MES) buffer, pH 6.0, and then combined for a total of 4 mL of 
purified T7 working stock.  Working stock of Phage T7TEV, which causes E. coli to overexpress 
tobacco etch virus protease and maltose binding protein upon infection, and working stock of 
Phage T7ALP which causes E. coli to overexpress alkaline phosphatase upon infection, were 
prepared as previously described 151, 152. For the sake of clarity, T7TEV will be referred to a T7MBP, 
as we are interested in MBP production for this application. The titer of all T7 working stocks 
were determined following the double agar overlay plaque assay110.  
5.3.2 Phage Concentration Versus Cell Concentration Matrix 
For each matrix an overnight 50 mL culture of BL21, was grown at 37 °C in LB broth with 
shaking. OD was determined to confirm sufficient growth had occurred to achieve a 
concentration of approximately 109 CFU/mL. The overnight culture was serially diluted down to 
10-6 (~1000 CFU/mL) 10-7 (~100 CFU/mL), 10-8 (~10 CFU/mL), 10-9 (~1 CFU/mL) using LB broth. 1 
mL of the desired dilution was pipetted into the appropriate well in the 96-well DeepWell™ 
(ThermoFisher Scientific) plates. In case where the initial CFU/mL desired was 0, 1 mL of sterile 
LB broth was added to the well.  Each dilution series was plated on E. coli/coliform petrifilm (3M, 
St. Paul, MN) or spread plated on LB agar to confirm bacterial levels. 
The T7 working stock, which in all cases was in the 1011 PFU/mL range, was serially 
diluted down to desired levels (10-5, 10-6, 10-7, 10-8 ) in LB broth and 10 µL of the appropriate 
dilution was pipetted into the appropriate well to achieve an initial well PFU/mL of 104, 103, 102, 
and 101 respectively. In cases where the desired initial PFU/mL was 0, 10 µL of sterile LB broth 
was added to the well.  
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The 96-well plate was then incubated at 37 °C with shaking at 250 rpm for either 3, 5, or 
8 hours.  At the end of the desired incubation times, 100 µL of 5 M NaCl was added to each well 
to stop phage adsorption, and the contents of each well was passed through a 4mm 0.45 µm 
Millex®-HV filter (EMD Millipore) to remove any cells and cellular debris, and placed in the 
corresponding micro-centrifuge tubes and stored at 4 °C. Each tube was then tittered following 
the double overlay method to determine final PFU/mL.  All plates and time points were 
performed in triplicate. 
5.3.3 Lateral Flow Assay Construction 
T7 lateral flow strips were constructed as follows.  A 10 cm by 2.5 cm strip of 
nitrocellulose membrane (AE 98, Whatman International, Kent, England) was backed with a 10 
cm by 4 cm strip of PET plastic using 3M 465 adhesive transfer tape. For the test line, a solution 
of T7 tail fiber monoclonal antibody (EMD Millipore), which had been dialyzed overnight against 
PBS buffer pH 7.2, was printed across the backed membrane in a 95 mm line to achieve a 
concentration of ~0.2 μg of antibody per mm using the Linomat IV (Camag Scientific, Inc., 
Willmington, NC). The membranes were placed in a vacuum oven at 37 °C for 1 hour to dry. 
Membranes were then blocked in 1% non-fat dry milk powder, (Omniblok™, American 
Bioanalytical, Inc., Natick, MA) in PBS buffer, pH 7.2 with shaking for 30 minutes.  Membranes 
were then removed from the blocking solution, blotted dried, and then placed in PBS buffer, pH 
7.2, for 5 minutes with shaking to wash.  Membranes were removed from the wash solution, 
blotted dry, and further dried in a vacuum oven at 37 °C for 1 h. The membranes were removed, 
and an absorbent pad (CF5; Whatman International) was adhered to 1.5 cm PET overhang using 
3M 465 adhesive transfer tape. The membrane was then cut into 4 mm test strips. 
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MBP lateral flow strips were constructed following the method described for the T7 
lateral flow strips, except for the use of MBP polyclonal antibody PA1-989 (ThermoFisher 
Scientific) for the test line.  The MBP polyclonal antibodies were at a concentration of 1 mg/mL 
in PBS without glycerol, and therefore did not require dialysis. 19 μL of the antibody solution was 
used to achieve a concentration of 0.2 μg of antibody per mm of strip. 
ALP lateral flow strips were constructed following the method described for the T7 
lateral flow strips, except for the use of a polyclonal antibody ab7321 (Abcam, Cambridge, MA) 
against E. coli alkaline phosphatase for the test line.  The ALP polyclonal antibodies were at a 
concentration of 10 mg/mL and were diluted in PBS to concentration of 1 mg/mL. 19 μL of this 
antibody dilution was used to achieve a concentration of 0.2 μg of antibody per mm of strip. 
5.3.4 Lateral Flow Assay Procedure 
The T7 LFA was performed as follows: 50 μL of sample and 5 μL of 5% non-fat dry milk in 
PBS were placed in a small glass test tube, and the end of a test strip was then placed in the 
solution. Following absorption of the sample solution, the test strip was transferred to a glass 
tube containing 30 μL of PBS buffer, pH 7.2, resulting in a wash step. Once the buffer was 
absorbed, the test strip was placed on a heat block (50 °C) for 20 minutes. The heating step was 
found to be necessary in order to expose the target peptide sequence of the reporter antibody. 
A 10 μL solution containing the biotinylated T7 monoclonal capsid antibody (EMD Millipore) 
diluted 1:200 in PBS, pH 7, was then run up the strip, followed by 30 μL of PBS, pH 7.2, as a 
wash. Lastly, 5 μL of a 1:200 dilution in PBS of streptavidin conjugated QDot 605® (ThermoFisher 
Scientfic), was then run up the strip followed by 30 μL of PBS, pH 7.2, as a final wash.   
The MBP LFA was performed as follows: 50 μL of sample was incubated with 10 μL of 
biotinylated polyclonal MBP antibody diluted 1:200 in PBS, pH 7.2 for 10 minutes. The 
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biotinylated polyclonal MBP antibody was prepared using the EZ-Link™ Sulfo-NHS-Biotin kit 
(ThermoFisher Scientific) and is the same polyclonal MBP antibody used for the strip test line.  
After the incubation step, the sample was combined with 5 μL of PBS buffer, pH 7.2, containing 
2.5% non-fat dry milk 0.25% Tween 20 (ThermoFisher Scientific) in a small glass test tube, and 
the end of a test strip was placed in the solution.  Following absorption of the sample solution, 
the test strip was transferred to a glass tube containing 30 μL of PBS buffer, pH 7.2, as a wash. 
Next, 5 μL of a 1:200 dilution in PBS of streptavidin conjugated QDot 605® (ThermoFisher 
Scientific), was run up the strip followed by 30 μL of PBS, pH 7.2, as a final wash.   
The ALP LFA was performed as follows: 50 μL of sample was added to a small glass test 
tube, and the end of a test strip was placed in the solution.  Following absorption of the sample 
solution, the test strip was transferred to a glass tube containing 30 μL of PBS buffer, pH 7.2, as a 
wash. Finally the test strip was transferred to a glass tube containing, 1 mL of 1-Step™ NBT/BCIP 
Substrate Solution (ThermoFisher Scientific) pre-warmed to 37 °C, and incubated for two hours 
at 37 °C before reading.  
5.3.5 Bacterial Limit of Detection Using T7MBP and T7ALP 
Three separate overnight cultures of E. coli BL21 were serially diluted in LB to achieve 
103, 102, and 101 CFU/mL. A 900 µL aliquot of each dilution and a negative control of LB, 
containing no bacterial cells, were placed in wells of a 96-well DeepWell™ plate, and mixed with 
100 µL of 103 PFU/mL of T7MBP or 104 PFU/mL T7ALP in LB. The samples were incubated at 37 °C 
with 200 rpm shaking for 5 hours for T7ALP and 7 hours for T7MBP and T7ALP. Samples were then 
passed through a 4mm 0.45 µm Millex®-HV filter, stored at 4 °C, and tested as previously 
described using either the MBP or ALP lateral flow test trips, with exception that 100 μL of 
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sample, rather than 50 μL, was run up the strip.  The overnight cultures were serially diluted and 
plated on LB agar to confirm bacterial concentration.     
5.3.6 Bacterial Detection in River Water Using T7ALP 
River water, 2 L, was collected from Fort River in Amherst, MA and autoclaved. Three 
separate overnight cultures of E. coli BL21 were diluted and used to inoculate three separate 300 
mL aliquots of water at a target cocentration of 100 CFU/100 mL. 100 mL of water from each 
aliquot was then passed through a 0.22 µm SCFA filter, and 1 mL of LB was pulled back through 
the filter to re-suspend the captured cells. Each sample was added to a 15 × 100 mm glass test 
tube, resulting in three 1 mL tubes corresponding to each of the initial 300 mL river water 
aliquots. Then 100 µL of 105 PFU/mL of T7ALP in LB was added to one tube, and 100 µL of LB to 
the second, the contents of the third tube were plated to confirm level of E. coli recovery. The 
samples were incubated at 37 °C with 200 rpm shaking for 7 hours. Samples were then passed 
through a 4mm 0.45 µm Millex®-HV filter, stored at 4 °C, and tested as previously described 
using the ALP lateral flow test trips with exception that 100 μL of sample, rather than 50 μL, was 
run up the strip. The overnight cultures were serially diluted and plated on LB agar to confirm 
bacterial concentration.     
5.3.7 Image and Statistical Analysis 
Pictures of test strips were then taken using a digital camera, or in the case of fluorescent 
reporters, a CCD imaging station (Kodak, Rochester, NY, USA). Signal analysis, area under the 
curve, for the fluorescent reporters was performed using ImageJ (U.S. National Institutes of 
Health, Bethesda, Maryland, USA). The log10 of all test line signals was taken and then evaluated 
for statistically significance in Origin Pro version 9.0.0 (Northampton, MA).  All test line signals 
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were normalized to the test line signal of the negative control for the run, and then analyzed for 
significance using a single-sample, one-sided t-test, mean <=1, with an alpha level of 0.05. In all 
figures error bars represent one standard deviation (SD) ± from the sample mean and a star (*) 
indicates a significance (p < 0.05). 
5.4 Results and Discussion 
5.4.1 Impact of Phage-Cell Concentration and Time Dynamics 
A matrix was used to investigate the impact of starting cell concentrations, starting 
phage concentration, and incubation time on the dynamics of phage amplification. E coli BL21 
cells at concentrations of 0, 100, 101, 102, and 103 CFU/mL were incubated with 101, 102, 103, and 
104 PFU/mL of wild-type T7 phage and titered after 3, 5, and 8 hours. The resulting phage titers 
can be found in Figure 5.1.  We observed maximum phage amplification levels of 105.5, 108.5, and 
109.0 PFU/mL after 3, 5, and 8 hours of incubation, respectively, when starting with a cell 
concentration of 1000 CFU/mL.  We saw no detectable phage amplification with 3 hours of 
incubation when starting cell concentration were 100 CFU/mL, though observed a 107.5 PFU/mL 
max after 5 hours, and a 108.8 PFU/mL max after 8 hours. Again with 10 CFU/mL, we saw no 
detectable phage amplification with 3 hours of incubation, but observed a 106.0 PFU/mL max 
after 5 hours, and 108.1 PFU/mL after 8 hours.  With a 1 CFU/mL starting concentration we 
observed a 106.2 PFU/mL after an 8 hour incubation, and did not detect phage amplification for 
the other time points.  These maximum set the minimum level of sensitivity required for a phage 
amplification-based LFA, and provides us with some guidance for incubation time.  For example, 
depending on the sensitivity of the LFA, we could potentially detect amplification after an 8 hour 
incubation for all initial cell levels.  Conversely, we could not reasonable expect to detect 100 
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CFU/mL E. coli or less within 3 hours using this scheme as no observable phage amplification 
occurred during that time.  This does not necessarily mean no amplification occurred, only that if 
it did, the amount of phage did not greatly rise above the level of our initial phage inoculum.  
When using phage amplification as part of a detection scheme, it is important to note the 
impact of initial phage levels on final signal production. By increasing initial phage 
concentrations the likelihood of infection increases and thus the speed of amplification is 
similarly increased 153. This can be seen in Fig. 1 where we detected an increase in phage levels in 
as little as three hours when initial cells levels were 103 CFU/mL. Total phage produced, 
however, must be sufficient achieve a detectable signal by the assay being used.  We found that 
amplification levels were lower when our initial phage inoculum was at the highest level tested, 
104 PFU/mL.  A similar inverse relationship between starting and final phage levels has also been 
observed with other phage strains 154.  This is likely due to the dynamics underlying the 
interactions between cell replication and phage infection. Final phage levels are directly 
correlated to the total number of cells infected, the more cells there are the more phage 
produced. Lower initial phage concentrations result in slower infection rates. Additionally, it 
provides time for uninfected cells to double resulting in an increase in the total amount of cells 
available for infection and final phage levels, assuming that the time is sufficient to allow all cells 
to be infected. It is important to note that when using phage amplification to increase the signal 
from viable cells, a high inoculum titer is not necessarily better.  
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5.4.2 Lateral Flow Assay Limit of Detection 
We compared the limit of detection of three phage-amplification based lateral flow 
assays (Figure 5.2).  The first assay targeted the T7 phage virion itself, and used a fluorescent 
quantum dot reporter. The second assay targeted MBP, a peptide co-produced during T7MBP 
amplification, also using a fluorescent quantum dot reporter.  The third assay targeted alkaline 
phosphatase, an enzyme that is overproduced during T7ALP amplification, and whose activity was 
detected using the substrate BCIP/NBT, which results in the production of a visible, dark blue 
precipitate.   
Figure 0.14 Influence of initial phage and bacterial concentrations on phage-amplification with respect to time.  aTiter of all replicates were Too Few To Count, indicating no amplification had occurred during incubation.  bTiter of two replicates was TFTC, indicating no amplification occurred in those samples. cTiter of one replicate was TFTC, indicating no amplification occurred in one sample. In the cases of TFTC, the initial PFU/ml was used for calculate average and standard deviation.  Error bars represent one SD ± from the sample mean. 
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Dilution series of stock T7, T7MBP, and T7ALP were prepared in triplicate and tested using 
Figure 0.15 Lateral flow assay (LFA) Schematic. The LFA consists of a nitrocellulose membrane with a test line containing capture antibodies against either: (i) the tail fiber of T7; (ii) maltose binding protein; or (iii) E. coli alkaline phosphatase. Biotinylated secondary antibodies against either: (i) the leader sequence of capsid protein 10B of T7; or (ii) maltose binding protein; in combination with a streptavidin conjugated quantum dot reporter are used to produce a signal at the test line.  In the case of alkaline phosphatase strip, the membrane is placed in BCIP/NBT, and if phosphatase is present a dark blue precipitate is deposited at the test line. 
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the corresponding lateral flow assay.  The reporter signal produced at the test line was 
proportional to the corresponding phage titer of the sample and therefore used to determine 
the minimum level of phage amplification necessary to produce a signal.  The test line signal of 
each dilution series sample were analyzed using ImageJ and compared to the signal at the test 
line of the negative control strip for the series (Figure 5.3a).  A representative set of strips can be 
found in Figure 5.3b, these images were adjusted for brightness and contrast in order to better 
visualize the test line. For T7 assay, while one can visually distinguish a test line in samples 
containing at least 106.8 PFU (Figure 5.3b), statistically significant fluorescent signals were only 
observed at the test line in samples containing at least 107.8 PFU or wild type T7 (Figure 5.3a). 
With the MBP lateral flow assay, we were able to visually distinguish and detect a statistically 
significant test line signal in samples containing at least 106.2 PFU of T7MBP (Figure 5.3). At the 
highest concentration tested, 108.2 PFU, a statistically significantly signal was not detected (p = 
0.0502).  Lastly with the ALP lateral flow assay we were able to visually distinguish and detect a 
Figure 0.16 LFA Limit of Detection. (a) 50 μL samples of a dilution series of wild-type T7, T7MBP, and T7ALP stock were tested using the T7 LFA, MBP, and ALP LFA, respectively.  Sample test line signals were normalized to the negative control test line signal (S/N) for all assays using the quantum dot reporter.  The dotted line denotes an S/N ratio = 1. Error bars represent one standard SD ± from the sample mean and a star (*) indicates a significance ( p < 0.05).  (b) Representative strips of T7, T7MPB, and T7ALP LFA trials. The left most strip corresponds to the negative control, and each subsequent strip is increasing phage titer corresponding to the respective data points in part a. 
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statistically significant test line signal in samples containing at least 105.5 PFU of T7ALP (Figure 5.3). 
Based on a sample volume of 50 µL, the final phage amplification levels required for detection 
were calculated to be: 109.1 PFU/mL of wild-type T7; 107.5 PFU/mL of T7MBP, and 106.8 PFU/mL of 
T7ALP.  Thus using a peptide reporter produced by a bioengineered T7, we lowered the required 
phage-amplification levels for a detectable signal by 1.6 log10, a great than 10-fold increase in 
sensitivity.  Using the alkaline phosphatase reporter further reduced necessary phage-
amplification levels by a total of 2.3 log10, greater than 100-fold improvement in sensitivity.  
These results highlight the potential of targeted bioengineering of phage to produced reporter 
molecules that can enhance the performance of phage amplification-based LFAs. 
 
5.4.3 Detection of E. coli in Broth Using T7MBP and T7ALP Amplification-based Lateral Flow Strips 
As previously noted, the phage amplification matrix (Figure 5.1) provided guidance on 
the maximum phage amplification we could expect over time based on starting cell 
concentrations.  While we were able to detect phage virions using the T7 LFA, none of phage 
amplification observed surpassed the 109.1 PFU/mL limit of detection for the T7 LFA.  This 
suggests, at when cells concentrations are 1000 CFU/mL, that a T7-targeted LFA would not be 
adequate for successful detection of E. coli.  
The phage amplification matrix also indicated that a starting cell concentration of 1 
CFU/mL would not result in phage amplification sufficient to trigger detection in either of our 
bioengineered phage-based LFAs.  For the MBP reporter, which has a detection limit of 107.5 
PFU/mL, there was one case where a starting cell level of 10 CFU/mL resulted in an average 
phage amplification level greater than 107.5 PFU/mL, however there was a lot variability for that 
data point.  We saw maximum phage amplification levels after 8 hours for starting cell 
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concentrations of 100 and 1000 CFU/mL with an initial phage inoculum level of 102 PFU/mL, so 
we chose this inoculum level for further T7MBP testing.  We saw phage amplification greater than 
T7ALP LFA limit of 106.8 PFU/mL for initial cell concentrations of 10 CFU/mL and greater, when 
initial phage inoculum levels were 104 PFU/mL. We therefore chose this inoculum level for 
further T7ALP testing.  
We incubated several concentrations of E. coli BL21, from 101 to 103 CFU/mL, and a 
negative control of LB in the absence of target bacteria, at 37 °C with an inoculum of either T7MBP 
or T7ALP, for 7 hours for the former, and 5 and 7 hours for the later.  At the end of incubation, we 
filtered the samples to remove cellular debris, and ran a 100 µL aliquot up the appropriate 
lateral flow strip as previously described. Note, an added benefit of doubling the volume of the 
sample aliquot to 100 µL, is that it lowers the amount of phage amplification needed to be 
reached in the sample by 0.3 log10, i.e for T7ALP, the necessary level went from 106.8 PFU/mL to 
106.5 PFU/mL and from 107.5 to 107.2 for T7MBP. A statistically significant signal from phage 
amplification could be detected at the test line from samples with an initial bacterial 
concentration of 103 CFU/mL for both T7MBP after 7 hours and T7ALP after 5 hours (Figure 5.4a).  
We were able to detect a statistically significant signal from T7ALP amplification after a 7 hour 
incubation from a starting concentration of 102 and 103 CFU/mL of E. coli (Figure 5.4a).  Based on 
the phage amplification matrix (Figure 5.1), we had expected to see signal from T7ALP 
amplification at 101 CFU/mL, but did not.  It is possible that both the 1 hour decrease in 
incubation was sufficient to prevent amplification levels from reaching those observed within 8 
hours in our earlier matrix.  It is also possible that the insertion of alkaline phosphatase into the 
T7 genome, and its subsequent overexpression during infection could lower the amplification 
efficiency of the bioengineered T7ALP in comparison to the wild type used for the matrix, and 
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thus not achieve the same level of amplification.  The T7ALP strips were allowed to develop in 
BCIP/NBT overnight, and a visually detectable line did form at the test line for 101 CFU/mL 
samples (data not show). 
 
5.4.4 Proof-of-Principle Detection of E. coli in river Water Using T7ALP Amplification-based Lateral Flow Strips 
E. coli is commonly used as an indicator of drinking and recreational water quality155, and 
the rules for produce safety proposed by the FDA as part of the Food Safety Modernization Act 
(FSMA) will also establish microbiological quality criteria for agricultural water.  These produce 
safety rules will require regular water monitoring for generic E. coli with a rolling 5-sample mean 
limit of 126 CFU/100 ml and a statistical threshold value of 410 CFU/100 mL156.   While there are 
many commercially available tests to detect E. coli in water, the majority of these tests take 
anywhere from 24-48 hours to provide results36. This time delay presents significant challenges 
Figure 0.17 Bacterial Detection. (a) Samples of each E. coli concentration were tested with the corresponding LFA following either a 5 or 7 hour incubation at 37 °C with T7ALP or T7MBP; (b)  River water containing 100 CFU/100 mL of E. coli was filter concentrated and cells re-suspended in LB with (+) or without (-) T7ALP and incubated for 7 hours at 37 °C.  100 μL of each samples were tested with the ALP LFA.  In both graphs sample test line signals were normalized to the negative control test line signal (S/N). The dotted line denotes an S/N ratio = 1. Error bars represent one SD ± from the sample mean and a star (*) indicates a significance ( p < 0.05). 
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for farmers in regards to water use management and appropriate corrective action response to 
the discovery of non-complaint water.   
Our bacterial limit of detection using T7ALP amplification was 100 CFU/mL, essentially two 
orders of magnitude higher that the FSMA agricultural water limit.  Filtration of 100 mL is a 
commonly used method for bacterial concentration when performing E. coli testing of water.  To 
explore whether this concentration step would help us to reach the essentially 1 CFU/mL FSMA 
limit, we took 100 mL samples of sterilized river water and spiked them with ~100 CFU of E. coli 
strain BL21, passed them through a 0.45 µm filter to capture the cells.  We pulled 1 mL of LB 
back through the filter to re-suspend the cells and inoculated with T7ALP. To further demonstrate 
that any positive signal was due to alkaline phosphatase production from T7ALP amplification and 
not due to alkaline phosphatase endemic to E. coli, our negative controls were samples spiked 
with E. coli that were not subsequently inoculated with phage.  Samples were incubated for 7 
hours at 37 °C.  A 100 µL aliquot of each of these samples was tested using the T7ALP LFA, and the 
strips developed in BCIP/NBT for 2 hours. Pictures were taken and analyzed for signal.  We were 
able to detect a statistically significant signal at the test line in the samples inoculated with T7ALP, 
and detected no signal in negative controls (Figure 5.4b).  This proof-of-principal demonstrates 
the potential for phage amplification-based LFAs to rapidly detect regulatory relevant levels of 
bacteria, though further work is needed to explore the impact of other microbial organisms that 
would be co-concentrated in the sample. 
5.5 Conclusion 
Our goal was to investigate the use of bioengineered phage to improve the sensitivity of 
phage-amplification based lateral flow assays for the detection of bacteria. We demonstrated 
that by bioengineering phage to overexpress peptide and enzymatic reporters, that we could 
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improve the sensitivity of phage-amplification based LFA by over 100-fold.  This increase in 
sensitivity enabled the detection 103 CFU/mL of E. coli after 7 hours, and a regulatory limit of 
100 CFU/100 mL of E. coli when combined with a filter concentration step in 9 hours. The LFA 
format is ideal for use in low-resource settings, such as some clinics, farms, and food production 
facilities; and modern molecular techniques allow for the replication of our alkaline phosphatase 
reporter scheme in other phage to ensure broad species coverage and allows for the targeting of 
other bacterial species of significance. Further research into LFA-amenable phage-delivered 
reporter peptides and enzymes will unlock the power and sensitivity of phage-based diagnostics, 
allowing for the development of novel and versatile bacterial detection assays. 
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